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Dear Reviewers, dear members of the Editorial Board  
 
Thank you for the kind and thorough review of our manuscript. We hope we have 
addressed all questions sufficiently and have made all suggested changes in the re-
submission.  
 
Editor requests 
1) You may consider to cite some of the previously published papers from the SHARE 
initiative - to put the current paper into a wider context. 
 
Response: We have added the following publication in addition to the "Time to SHARE" 
reference (REF 4):  
 
• European evidence-based recommendations for diagnosis and treatment of 
childhood-onset systemic lupus erythematosus: the SHARE initiative. Groot N, 
Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, Feldman B, Kone-
Paut I, Lahdenne P, Marks SD, McCann L, Ozen S, Pilkington C, Ravelli A, Royen-
Kerkhof AV, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW. Ann 
Rheum Dis. 2017 Jun 19. pii: annrheumdis-2016-210960. doi: 
10.1136/annrheumdis-2016-210960. [Epub ahead of print] 
• Recommendations for the management of autoinflammatory diseases.ter Haar 
NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti 
C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, 
Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert 
SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner 
JB.Ann Rheum Dis. 2015 Sep;74(9):1636-44.  
• Consensus-based recommendations for the management of juvenile 
dermatomyositis. Enders FB, Bader-Meunier B, Baildam E, Constantin T, 
Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, 
Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, 
Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Ann Rheum Dis. 
2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 
Aug 11. Review. 
•  European evidence-based recommendations for diagnosis and treatment of 
paediatric antiphospholipid syndrome: the SHARE initiative.Groot N, de Graeff N, 
Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, 
Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, 
Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW. 
Ann Rheum Dis. 2017 May 4. pii: annrheumdis-2016-211001. doi: 
10.1136/annrheumdis-2016-211001. [Epub ahead of print] 
(page 5)  
 
2) Supplemental Table 2 should be supplementary Table S1. 
Response: We made the change as suggested (see online supplementary material). 
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3) I assume you plan to include what you now call appendix into the online supplement. 
If you need to add any material, please be aware that text, figures and tables can be 
published as online supplementary material. Online figures and tables should have 
separate numbers – Figure S1, S2 etc, Table S1, S2 etc. You may refer to the 
supplementary material in the main text as follows: (see online supplementary text / 
online supplementary Table S1, S2 etc /online supplementary Figure S1, S2 etc – as 
appropriate). 
Response: Yes, thanks for the kind suggestion.  We modified the titles accordingly (see 
online supplementary material). 
 
FORMATTING AMENDMENTS 
 
1) Tables meant for print publication should not exceed 2 pages. If they are, reduce the 
size or upload them as Supplementary file, to be published as Online only. 
Response: We have modified the format of Table 1 as requested in two ways, a 
landscape format with 8pt fond and a removal of all explanatory text (option 2). These 
two options are submitted together as a separate document.  However, we strongly 
believe Table 1 should be kept in the document in the original version and not be moved 
to the online supplementary material, since it is of key interest for the readers.  
 
2) Please make sure the following statements are included in the main document file, 
which should match the details given in the submission pages: Competing interests, 
Acknowledgements, Contributorship, Funding info 
Response: We modified the main document as requested and added the following 
statements:  
Competing interests: None declared.  
Acknowledgements: None. 
Contributorship: All authors have contributed to the study design, data gathering, 
analysis and preparation of the submitted manuscript.  
Funding info: SHARE was funded by the European Agency for Health and Consumers 
(EAHC), No. 2011 1202. 
(see page 3)  
 
Reviewer 1 
1) Comment to the author: The authors have proposed a SHARE model for conducting 
research in pediatric Rheumatology. Overall the manuscript details the procedure 
followed in arriving at a consensus.  
Response: Thank you very much for the important comment. The manuscript is the 
reflection of the process resulting in the evidence-based and consensus-supported 
proposed recommendations for collaborative paediatric research. We are hoping these 
are capturing the complexity of the process and will be helpful in advancing 
collaborative paediatric research including biobanking.  
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2) The reason for changing from the UNESCO International Declaration on Human 
Genetic Data the right of an individual to decide whether or not to be informed of the 
results of genetic tests are not very clear. I am not sure if it is a barrier to participation. If 
mutation for Huntigton's chorea is found in GWAS study would it be told to family. 
Response: The reviewer raises a critically important challenge in pediatric research. 
While the "right to not know" is clearly defined in the UNESCO International Declaration 
on Human Genetic Data and fully applicable for adults, the situation for children is more 
complicated. In paediatric research, the decision maker commonly is the parent or legal 
guardian not the participating child. Information generated in research studies that have 
to result in medical attention ("clinically relevant results") have to be shared in order to 
facilitate treatment for the child (see Hens 2011). This is reflected in the proposed 
recommendations. Refusal to be informed about clinically relevant results therefore has 
to represent an exclusion criterion for participation in pediatric research studies. 
We modified the results as follows  
"Refusal to be informed about clinically relevant findings therefore represents a barrier 
for the participation of minors in research
25
; parents cannot make the choice for their 
children not be informed about clinically relevant results." (page 12).  
 
3) Appendix can be moved to supplementary data 
Response: we moved the appendix to the online supplementary material (see Table S2) 
 
Reviewer: 2 
 
1) The language is mostly clear and concise. Some mistakes like “focussing” (twice in 
page 7), and “a” instead of “an” etc several places should be corrected  
Response: We removed the repeated mistakes of “focussing” on page 6. We also 
corrected the wrong "a" used in the text throughout the document. 
 
2) The abstract is appropriate 
Response: Thank you. 
 
3) METHODS are sound, adequate for the task, and precisely described 
Response: Thank you. 
 
4) METHODS and FIGURE 1 
a)      It is unclear to me if the inclusion of normative documents as level 1 in the 
modified hierarchy of evidence pyramid, while systematic reviews and RCT are level II a 
and II b, is a construction of the authors? I was not able to find this approach at the 
CEBM website in the references. Please clarify  
Response: The reviewer raises a critically important question, which we have struggled 
with and proactively addressed when conducting the research. Similar to the reviewer, 
we were unable to find a publication defining the assigned evidence level of normative 
documents. Rather than constructing our own evidence ranking, we connected with the 
Cochrane Foundation directly and were instructed to rank normative documents as level 
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1 evidence. We referred to this as "modification of the evidence ranking system 
supported by the Cochrane group" (page 6).  
 
 
b)      International normative documents have been used in this manuscript as level 1 in 
the modified hierarchy of evidence pyramid, while systematic reviews and RCT are level 
II a and II b. All recommendations for collaborative paediatric research must of course 
be in line with these normative documents. However, regulations, guidelines, and 
legislation may change with rapidly evolving registries, biobanking, genetic, and other 
research possibilities, even though the Human rights and Helsinki declarations are 
constant. I would suggest to have the international normative documents as a 
background triangle outside all the levels of the pyramid, rather than at the top of the 
pyramid, and could still be designated Grade A of Recommendation. The other approach 
is the choice of the authors, and the whole manuscript cannot be changed after the 
nominative group process has taken place.  
Response: Thanks you for the great suggestion. We modified Figure 1 as requested.  
 
I still challenge the authors to discuss this choice of comparing normative documents 
with scientific papers in the DISCUSSION section. 
Response: Thank you for the kind encouragement. We modified the Discussion as 
requested.  
"This framework is the first of its kind. It was built upon a comprehensive review of 
published evidence, guidance of European leaders in ethics and law, and practical 
experience of leading paediatric researchers, and expert clinicians. Normative 
documents including ratified European laws and international declarations were 
reviewed and served as high-level evidence, an approach common to the area of ethics 
research, yet unfamiliar to medical researcher. Most importantly, the process has 
integrated the perspective of families living with childhood rare diseases." (page 13) 
 
5)  METHODS Page 9, line 46, Please state the evidence level after “cross-sectional 
studies”.  
Response: We added the level of evidence as requested and modified the manuscript as 
follows: "Among the 85 retained publications three publications were systematic 
reviews, defined as evidence level II a (none were II b), 15 were non-systematic reviews 
(evidence level III), 24 cross-sectional studies (level IV b), 16 narrative reviews, and 27 
expert opinions (evidence level V b)." (page 9) 
 
6)  DISCUSSION section. The authors state that the key limitation of the study is the lack 
of generalizability beyond Europe. Please discuss how this problem could be solved (i.e 
the current work as a model for other regions, inviting other regions and especially less 
privileged countries to participate in Paediatric Rheumatology collaborative research 
initiatives across borders, etc)  
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Response: Thanks for encouraging to further discussing this important aspect. We have 
expanded on the limitation of generalizability as requested and modified the discussion 
as follows: 
"There are several limitations to the study and its results. The key limitation is the 
generalizability beyond Europe. Published literature and normative documents 
applicable to the European context only informed the recommendation development. 
The transferability into another cultural context such as North or South America has to 
be explored. When aiming so, the literature search and evidence synthesis would have 
to include publications and most importantly normative documents beyond Europe. In 
addition, the expert team had a content and method focus on childhood rheumatic 
diseases. In or er to increase the generalizability care researchers, patients and families 
with a spectrum of other conditions including common and rare, acute and chronic 
illnesses would need to be part of the process. The transferability to other childhood 
diseases could then be tested; recommendations may require additional specifications 
when applied to a different disease context. However, it appears that principles 
captured in the proposed set of recommendations are widely generalizable across 
childhood diseases." (page 14) 
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 4 
Abstract  
Objectives: Innovative research in childhood rheumatic diseases mandates international 
collaborations. However, researchers struggle with significant regulatory heterogeneity; an 
enabling EU-wide framework is missing. The aims of the study were to systematically review 
the evidence for best practice and to establish recommendations for collaborative research. 
Methods: The Paediatric Rheumatology European SHARE project enabled a scoping review 
and expert discussion, which then informed the systematic literature review. Published 
evidence was synthesized; recommendations were drafted. An iterative review process and 
consultations with Ethics Committees and European experts for ethical and legal aspects of 
paediatric research refined the recommendations. SHARE experts and patient 
representatives vetted the proposed recommendations at a consensus meeting using 
Nominal Group Technique. Agreement of 80% was mandatory for inclusion.  
Results: The systematic literature review returned 1319 records.  A total of 223 full-text 
publications plus 22 international normative documents were reviewed; 85 publications and 
16 normative documents were included. A total of 21 recommendations were established 
including general principles (1-3), ethics (4-7), paediatric principles (8 and 9), consent to 
paediatric research (10 -14), paediatric data- and biobanks (15 and 16), sharing of data and 
samples (17 - 19), and commercialization and third parties (20 and 21). The refined 
recommendations resulted in an agreement of >80% for all recommendations.  
Conclusions: The SHARE initiative established the first recommendations for Paediatric 
Rheumatology collaborative research across borders in Europe. These provide strong 
support for an urgently needed European framework and evidence-based guidance for its 
implementation. Such changes will promote research in children with rheumatic diseases.  
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 5 
Introduction  
Paediatric rheumatic diseases are rare and often devastating; advancing knowledge and 
improving care and outcomes of affected children mandates research collaborations across 
national borders 
1-3
. Across Europe, several national innovative research teams have made 
substantial contributions to developing clinical tools, biomarkers, and imaging strategies for 
children with rheumatic diseases. Their evaluation and implementation mandates 
international patient cohorts and research partnerships given that some paediatric 
rheumatic diseases have incidences as low as one per million. 
The European community strongly encourages collaborative international research and 
funded the “Single Hub and Access point for paediatric Rheumatology in Europe (SHARE)" 
initiative, which aims to optimize care and research for children with rheumatic diseases 
across Europe
4-8
.  A key task was the identification of barriers between nations for 
collaborative Paediatric Rheumatology research. Currently, researchers funded to conduct 
important studies struggle with the substantial heterogeneity within and across European 
countries in all areas of rare diseases research. These include ethics approval process, 
consent and assent, formal frameworks for data and sample collection and sharing, and 
aspects of third party data and sample access. Currently there is no EU-wide framework 
facilitating the conduct of collaborative rare diseases research
9
. 
Therefore the aims of the study were to synthesize the evidence for best practice in 
paediatric rheumatic diseases research and to develop recommendations to enable research 
collaborations including data- and biobanking across Europe. 
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 6 
Methods 
Scoping review and expert consultation 
A scoping review on collaborative paediatric research was conducted identifying key themes. 
In addition, major stakeholders including ethics committee members, European Paediatric 
Rheumatology researchers, and patients with rare diseases were asked to provide input 
regarding their perspectives on research and its barriers and challenges using structured 
interviews by surveys, phone, and in-person. The group identified key themes and 
constructed an evaluative framework including a modification of the evidence ranking 
system supported by the Cochrane group (Figure 1).  
 
Systematic review  
Search strategy and selection criteria 
A systematic literature review anchored in the identified key themes was performed and 
reported according to the standards of the “Preferred reporting items for systematic review 
and meta-analysis protocols (PRISMA)” guidelines
10,11
. This systematic search of the 
literature aimed to identify studies of all aspects of paediatric research in Europe. These 
were specified in MESH terms and subheadings including data collection, ethics, biological 
specimen banks, confidentiality, informed consent by minors, specimen handling, 
jurisprudence, quality improvement, legislation, classification, methods, organization, 
administration, standards, and instrumentation. The search was performed in the electronic 
databases PubMed and Web of Science on 14th May 2014. The search was limited to articles 
published in English and children and adolescents (ages 0-18 years); the search period was 
set between January 1989 and April 2014, guided by the publication date of the United 
Nation's Convention on the Rights of the Child
12
. In addition to the electronic literature 
search, a manual review of the references of all relevant publications and international and 
European normative documents was conducted. Articles were excluded, if the content was 
not related to children and adolescents, it did not apply to the European context, or to any 
aspect of collaborative paediatric research.  
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 7 
Data extraction and validity assessment  
The remaining full-text articles were reviewed by a panel of experts, graded by two 
independent researchers, and reconciled by a third using predefined scoring instruments for 
the different study and publication types as appropriate
13,14
. The following variables were 
abstracted: reference, year of publication, authors, country of focus, and contribution to the 
themes. Levels of evidence and strength of recommendations were determined using an 
adjusted framework for grading scientific evidence in order to account for normative 
documents including declarations, regulations, guidelines, and legislative documents
15
. 
 
Development and refinement of recommendations 
Grouped by distinct themes, the evidence was synthesized; additional domains were 
developed including public opinion on paediatric research, guidelines, and jurisdiction. 
Recommendations were drafted. In-depth discussion, iterative reviews, and adjustments of 
the recommendations were completed with ethics committee staff members and 
international content experts in paediatric ethics (KH) and legislation (DS). The draft version 
of the recommendations was sent to all SHARE experts in an online survey format for review 
and revision. All suggestions were integrated and additional recommendations were drafted; 
the revised documents were re-distributed to the experts for review and evaluation of 
agreement.  
 
Consensus meeting 
The proposed and reviewed recommendations were presented to the SHARE expert 
committee and patient representatives during a face-to-face consensus meeting in Rome, 
Italy, and discussed in-depth using Nominal Group Technique
16
. Recommendations were 
accepted by reaching agreement above 80%.  
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Results 
Scoping review and expert consultation  
The key themes of collaborative paediatric research and biobanking in Paediatric 
Rheumatology were identified. These included ethics, legislation, consent, scope of consent, 
confidentiality, anonymisation, sample and data collection, handling, and storage. These 
were translated into search terms to inform the evidence synthesis.  
 
Systematic literature review  
The initial search returned 7347 records, of which 6503 had to be excluded. Ultimately, 1319 
publications including 844 from PubMed and 475 papers from the Web of Science Core 
Collection were identified. After removing 31 duplicates, a total of 1288 records were 
manually reviewed for title and abstract excluding 1065. Full-text assessment of 223 papers 
resulted in exclusion of 161. A total of 62 publications plus an additional 23 identified by 
targeted hand-search from references resulted in 85 papers to be included (see Table S1). A 
full-text review of 22 normative documents yielded 16 relevant documents including three 
international declarations, five guidelines, four European legislative documents, and four 
recommendations (see Table S2 and Figure 2).  
 
Data extraction and validity assessment  
Among the 85 retained publications three publications were systematic reviews, defined as 
evidence level II a (none were II b), 15 were non-systematic reviews (evidence level III), 24 
cross-sectional studies (level IV b), 16 narrative reviews, and 27 expert opinions (evidence 
level V b). All 16 normative documents were found to be evidence level I. 
 
Development and refinement of recommendations 
Evidence was translated into draft recommendations. Themes identified were the following: 
guiding principles, ethics, paediatric principles, consent to paediatric research, paediatric 
data- and biobanks: operational principles, sharing of data and samples, commercialization, 
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 9 
and third party access. In an iterative process draft recommendations were reviewed and 
refined by consulting experts and the European SHARE panel.  
 
Consensus meeting 
A total of 21 recommendations were drafted, grouped into the domains of Guiding Principles 
(Recommendation 1 - 3), Ethics (Recommendation 4 -7), Paediatric Principles 
(Recommendation 8 and 9), Consent in Paediatric Research (Recommendation 10 - 14), 
Paediatric Data- and Biobanks: Operational Principles (Recommendation 15 and 16), Sharing 
of Data and Samples (Recommendation 17 - 19), and Commercialization and Third Party 
Access (Recommendation 20 and 21).  Face-to-face discussion further refined all 
recommendations resulting in an agreement of >80% for all at the final consensus 
conference. 
 
Recommendations  
Guiding Principles  
The 2006 European Regulation No 1901/2006 of the European Parliament and of the Council 
on Medicinal Products for Paediatric Use (Paediatric Regulation) for the first time mandated 
the development and submission of an investigation plan for children at early stages of drug 
development in Europe
17
. The regulation emphasized the specific needs of children and 
aimed to end their status as “therapeutic orphans”
17,18
. In 2009, the EU Council published an 
action plan for rare diseases strongly encouraging Europe-wide collaborative studies 
including establishing sustainable infrastructure such as registries and biobanks
2
.  The plan 
mandated support for research training and sharing of tools and expertise across Europe. It 
emphasized the need for the development of European guidelines and recommendations for 
evaluation and treatment of rare diseases
2
. The 7
th
 Framework Program of the EU for 
Research 1982/2006/EC, Technological Development and Demonstration Activities 
encouraged the investigator-driven development of collaborative research networks, further 
building of European research capacity, and sharing of data and specimens
19
. In 2013, the 
Biobanks and Biomolecular Resources European Research Infrastructure Consortium 
(BBMRI-ERIC) was charged with the development of the Europe-wide research infrastructure 
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 10
of biobanks
3
.  These general principles for collaborative paediatric research in Europe are 
captured in Recommendations 1 - 3 (Table 1). 
 
Ethics  
The 2008 International Ethical Guidelines for Epidemiological Studies prepared by the 
Council for International Organizations of Medical Sciences (CIOMS) and the World Health 
Organization (WHO) defined that all proposals to conduct research in human subjects must 
be submitted for r view of scientific merit and ethical acceptability to review committees. It 
specified that ethics committees should establish working rules regarding frequency of 
meetings, a quorum of members, decision-making procedures, and review of decisions. The 
guidelines specified that the committee should provide its rules to prospective 
investigators
20
. In 2014, the Regulation 536/2014 of the European Parliament and of the 
Council on Clinical Trials on Medicinal Products for Human Use (Clinical Trials Regulation) 
aimed to simplify and harmonize the administrative provisions of clinical trials in Europe
21
. It 
mandated the submission of a single application dossier to all the Member States concerned 
through a single submission portal. The regulation defined that member states were to 
determine the appropriate body to be involved in the assessment of the application and to 
organize the involvement of ethics committees within a specific timeline of the trial. It 
further specified that the designated ethics committee had to have appropriate expertise 
and membership to review the application
21
. Concepts of centralization, transparency, and 
organizational expertise of ethics committees are captured in Recommendations 4 - 7 (Table 
1). 
 
Paediatric Principles  
The 1989 Convention on the Rights of the Child defined principles founded on respect for 
the dignity and worth of each child, regardless of race, colour, gender, language, religion, 
opinions, origins, wealth, birth status, or ability
12
. The Convention aimed to protect children, 
to help secure their basic needs, and to enhance the possibility of reaching their best 
potential
12,22
. The World Medical Association statement of the Declaration of Helsinki of 
Ethical Principles for Medical Research Involving Human Subjects emphasised the 
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importance of special protection of vulnerable populations including children
23
. It specified 
that medical research with a vulnerable group such as children is only justified, if the 
research is responsive to the health needs and priorities and cannot be carried out in a non-
vulnerable group
23
. The benefit of participating in a research study has to outweigh the 
potential risk
21
. The principle of minimal risk is a virtual standard for research in children
24
. 
Minimal risk is considered a risk that is similar to the child’s risk in everyday life
22
 and should 
not be greater than the risk attached to a routine medical examination
25
. The 2014 Clinical 
Trials Regulation specified that research in children should be performed out of necessity 
and a presumed benefit for the minor directly or for children with the same condition
21,24
. 
The principles of subsidiarity and the paediatric rule are captured in the Recommendations 8 
and 9 (Table 1). 
 
Consent in Paediatric Research  
The 2008 CIOMS/WHO International Ethical Guidelines for Epidemiological Studies 
mandated that before undertaking research involving children the investigator must ensure 
that a parent or legal representative of each child has given permission. In addition, the 
agreement of each child (assent) has to be obtained to the extent of the child’s capability
20
. 
It demands that the investigator must convey the information in language suitable to the 
individual child’s level of understanding and abilities. The consent/assent process has to 
include provision of sufficient time and opportunities for clarification
20
. The 2009 
Organization for Economic Co-Operation and Development (OECD) Guidelines on Human 
Biobanks and Genetic Research Databases suggested participants should be given a range of 
possible scopes of consent to choose from including broad consent to minimize potential risk 
of harm. In addition, the participant’s right to withdraw from the research at any time has to 
be emphasized
26
.  The 2016 Recommendation CM/Rec (2016)6 of the Committee of 
Ministers to Member States on Research on Biological Materials of Human Origin defined 
that re-consent has to be obtained, when a person attains capacity to consent
27
. It also 
mandated that clear policies should be in place ensuring communication of concerning 
findings that are relevant for the health of the persons – the so-called incidental findings
27
.  
While in adults based on the UNESCO International Declaration on Human Genetic Data the 
right of an individual to decide whether or not to be informed of the results of genetic 
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examinations should be respected
28
, the importance to act in the best interest of minors 
may override this right in children
29
. Refusal to be informed about clinically relevant findings 
therefore represents a barrier for the participation of minors in research; parents cannot 
make the choice for their children not be informed about clinically relevant resultsh
29
. The 
concepts of consent/assent, withdrawal of consent, re-consenting, and incidental findings in 
paediatric research are captured in the Recommendations 10-14 (Table 1). 
 
Paediatric Data- and Biobanks 
The 2009 OECD Guidelines on Human Biobanks and Genetic Research Databases mandated 
that data- and biobanks should be governed by principles of transparency and accountability 
including a clear formulation of governance structure and responsibility for its 
management
26
. It also demanded that operators should have protocols and processes in 
place to protect participants’ personal and medical information.  The 2013 European 
Commission Implementing Decision of the Biobanking and Biomolecular Resources European 
Research Infrastructure Consortium(BBMRI-ERIC) was charged with establishing and 
operating a pan-European research infrastructure including improved interoperability of 
data- and biobanks
3
.  It also mandated the implementation of quality management including 
standardized procedures and best practices. The 2016 Recommendation CM/Rec (2016)6 of 
the Committee of Ministers to Member States on Research on Biological Materials of Human 
Origin demanded safeguards to be put in place to ensure confidentiality at the time of 
collection, storage, and transfer of biological materials
27
 . The 2016 Regulation 2016/679 of 
the European Parliament and the Council, the General Data Protection Regulation, 
mandated special protection of information originating from children
30
. The concepts of 
organisation and conduct of paediatric data- and biobanks are captured in the 
Recommendations 15-21 (Table 1). 
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Discussion 
The SHARE initiative developed the first European recommendations for collaborative, 
paediatric research including biobanking for children with rheumatic diseases. A 
comprehensive systematic literature review including European legislative documents and 
an iterative consensus procedure was completed. A total of 21 recommendations were 
developed, refined, agreed on by expert clinicians in childhood disease, methodologists, 
paediatric researchers, and content experts of paediatric ethics and legislation, partnered 
with patient representatives. These recommendations will provide a robust framework for 
collaborative European research in rare childhood diseases in multicentre studies and the 
European Reference Networks (ERN) that are currently being created.  
Transformative European research in childhood diseases increasingly requires Europe-wide 
collaborations. This is particularly important for rare diseases such as the entire spectrum of 
rheumatic diseases of childhood. The proposed framework of recommendations includes 
concepts of guidance and support for collaborative research teams. It advocates increasing 
the competency and transparency of a proposed centralized ethics committee review 
processes of childhood rare diseases, as successfully modelled by the 2014 European 
Regulation on Clinical Trials 
21
. It provides evidence-based, structured guidance for all 
aspects of consent, data harmonization, and standardization of bio-specimen SOPs across 
Europe. This framework is the first of its kind. It was built upon a comprehensive review of 
published evidence, guidance of European leaders in ethics and law, and practical 
experience of leading paediatric researchers, and expert clinicians. Normative documents 
including ratified European laws and international declarations were reviewed and served as 
high-level evidence, an approach common to the area of ethics research, yet unfamiliar to 
medical researcher. Most importantly, the process has integrated the perspective of families 
living with childhood rare diseases. While being constructed in the context of the European 
Union funded research grant for paediatric rheumatic diseases, it is thought that it is likely to 
be transferrable to all collaborative childhood rare diseases research.  
Research in children poses the unique challenge and requires the inclusion of specific 
considerations. Most importantly, children have the right of designated paediatric research 
to advance the understanding of childhood diseases and development of best therapies
31
. 
This right has to be balanced with the societal mandate to protect children from harm
12
. The 
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recommendations aim to strike this balance by including principles such as subsidiarity, the 
paediatric rule, the protection of minors, and the minimization of burden
22
. Special 
considerations were given to the integration of minors in the consenting process
32
. While 
consent is obtained from the legal guardian, minors have to be appropriately informed and 
have to have a voice in the decision making process
33
. It was emphasised that consent in 
paediatric research should be broad to minimize harm and that re-consenting is mandatory 
when minors reach legal age
27
. The possibility of clinically relevant, actionable incidental 
findings has to be taken into account
34
. Distinctly different from research in adults, refusal to 
be informed about these findings has to be considered an exclusion criterion for paediatric 
research study participation
29
.  
There are several limitations to the study and its results. The key limitation is the 
generalizability beyond Europe. Published literature and normative documents applicable to 
the European context only informed the recommendation development. The transferability 
into another cultural context such as North or South America has to be explored. When 
aiming so, the literature search and evidence synthesis would have to include publications 
and most importantly normative documents beyond Europe. In addition, the expert team 
had a content and method focus on childhood rheumatic diseases. In order to increase the 
generalizability care researchers, patients and families with a spectrum of other conditions 
including common and rare, acute and chronic illnesses would need to be part of the 
process. The transferability to other childhood diseases could then be tested; 
recommendations may require additional specifications when applied to a different disease 
context. However, it appears that principles captured in the proposed set of 
recommendations are widely generalizable across childhood diseases.  
 The SHARE initiative enabled the development of the first recommendations for Paediatric 
Rheumatology collaborative research including data- and biobanking and sharing across 
borders. These recommendations provide strong support for an urgently needed European 
legislative framework and evidence-based guidance for its implementation. Children with 
rheumatic conditions and the many others suffering from rare diseases should no longer be 
left behind when life-changing research discoveries can be made. 
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Figure legends 
Figure 1 
Modified hierarchy of evidence pyramid for inclusion of normative documents  
Legend: The pyramid depicting the hierarchy of evidence was modified with guidance of the 
Cochrane collaboration to enable the inclusion of all available scientific evidence and 
international normative documents in the systematic review.  
 
Figure 2 
Literature selection flow chart  
Legend: The search included the following MESH-terms: data collection, ethics, biological 
specimen banks, confidentiality, informed consent by minors, specimen handling, quality 
improvement, and jurisprudence. In addition, the following subheadings were used: 
legislation, classification, methods, organization, administration, standards, and 
instrumentation. The search was limited to literature relevant to the paediatric age group (0 
to 18 years of age) and to Europe.  
 
Search strategy  
((((((( "Data Collection/ethics"[Mesh] OR "Data Collection/legislation and 
jurisprudence"[Mesh] ))) OR (((((( "Ethics/classification"[Mesh] OR "Ethics/ethics"[Mesh] OR 
"Ethics/legislation and jurisprudence"[Mesh] OR "Ethics/methods"[Mesh] OR 
"Ethics/organization and administration"[Mesh] OR "Ethics/standards"[Mesh] ))) OR ethics)) 
AND (( "Biological Specimen Banks/classification"[Mesh] OR "Biological Specimen 
Banks/ethics"[Mesh] OR "Biological Specimen Banks/instrumentation"[Mesh] OR "Biological 
Specimen Banks/legislation and jurisprudence"[Mesh] OR "Biological Specimen 
Banks/methods"[Mesh] OR "Biological Specimen Banks/organization and 
administration"[Mesh] OR "Biological Specimen Banks/standards"[Mesh] )))) OR (((( 
"Confidentiality/ethics"[Mesh] OR "Confidentiality/legislation and jurisprudence"[Mesh] OR 
"Confidentiality/organization and administration"[Mesh] OR 
"Confidentiality/standards"[Mesh] ))) AND (( "Biological Specimen 
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Banks/classification"[Mesh] OR "Biological Specimen Banks/ethics"[Mesh] OR "Biological 
Specimen Banks/instrumentation"[Mesh] OR "Biological Specimen Banks/legislation and 
jurisprudence"[Mesh] OR "Biological Specimen Banks/methods"[Mesh] OR "Biological 
Specimen Banks/organization and administration"[Mesh] OR "Biological Specimen 
Banks/standards"[Mesh] )))) OR (( "Informed Consent By Minors/ethics"[Mesh] OR 
"Informed Consent By Minors/legislation and jurisprudence"[Mesh] OR "Informed Consent 
By Minors/organization and administration"[Mesh] OR "Informed Consent By 
Minors/standards"[Mesh] ))) OR ((((((( "Specimen Handling/ethics"[Mesh] OR "Specimen 
Handling/legislation and jurisprudence"[Mesh] ))) OR (("Specimen 
Handling/standards"[Majr]) AND "Quality Improvement"[Mesh])) OR (("Specimen 
Handling"[Mesh]) AND "Ethics"[Mesh])) OR (("Jurisprudence"[Majr]) AND "Specimen 
Handling"[Majr])) OR (((("Specimen Handling"[Majr]) And ("legislation and jurisprudence" 
[Subheading]))) OR (("Specimen Handling"[Majr]) AND "ethics" [Subheading]))))) OR (( "Data 
Collection/ethics"[Majr:NoExp] OR "Data Collection/legislation and 
jurisprudence"[Majr:NoExp] )) 
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Table 1 
Recommendations for collaborative paediatric research including biobanking in Europe 
 
Text of recommendations  Justification Evidence 
level 
Strength of 
recommen-
dation 
Agree-
ment 
Guiding Principles 
Recommendation 1: 
Advancing Care and Discovery  
Research in children should be 
supported including 
international, multi-centre 
data collection and banking 
and transfer of biological 
specimens. Collaboration 
enables discovery in paediatric 
diseases and care 
advancement for children, in 
particular for those with rare 
diseases. 
Discovery and care 
advancement in paediatric 
diseases requires collaborative 
longitudinal research projects 
of international scale in order 
to include sufficient numbers of 
participants and generate 
robust scientific data. The 
international collaborative 
collection, storage, and sharing 
of human biological material 
and associated clinical 
information reduce the overall 
burden of sampling for patients 
and researchers enabling 
sustained, high-quality 
research
2,17,18,22,33,35
. 
I B 100% 
Recommendation 2: Enabling 
Support 
Paediatric researchers should 
be offered research training 
opportunities, access to 
mentorship and guidance, 
protected time, and financial 
support to conduct paediatric 
research. Institutional 
resources for research 
protocol development, 
translation services, ethics 
submission, and research 
conduct should be made 
available. 
The complexity of collaborative 
paediatric diseases research 
and the heterogeneity of rules, 
regulations, and processes 
within and across European 
countries mandate researchers 
to develop distinct skill sets and 
content knowledge. Focused, 
comprehensive training, 
institutional assistance, and 
guidance partnered with 
financial and other support will 
enable researchers to 
overcome the disproportionally 
challenging barriers towards 
successful multi-national 
paediatric diseases research 
requiring sample and data 
I B 100% 
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collection 
2,20,28,36-38
. 
Recommendation 3: 
Supportive Legislative 
Framework 
A supportive legislative 
framework for international 
collaborating biobanks is 
lacking. A framework (WHO, 
ICH, EMA, FDA, other) should 
be implemented to overcome 
legal and ethical barriers in 
international research. An 
international binding 
shipment and custom 
agreement for biological 
samples should be 
established. 
The regulatory requirements 
for paediatric biobanking vary 
significantly between European 
countries. This dramatically 
complicates the implementing 
of international paediatric 
diseases biobanks. A unified 
European framework should be 
developed and implemented in 
order to facilitate the 
international sharing of 
precious paediatric 
biospecimen and enable life-
saving discoveries 
3,24,33,37,39-42
. 
II B 100% 
Ethics 
Recommendation 4: 
Centralized Ethics  
All international collaborative 
paediatric research should be 
reviewed by central European 
Ethics Committees. All 
auxiliary studies require 
additional review and 
approval. The review has to 
capture all ethical principles 
including privacy rights. 
Designated and highly qualified, 
independent, and centralized 
Ethics Committees should serve 
as Competent Authority for 
paediatric research. 
Subsequent, auxiliary studies 
should be reviewed by the 
same committee. The resulting 
single ethics vote captures the 
highest ethical principles and 
privacy standards. 
Subsequently National Ethics 
Committee reviews are solely 
tasked with evaluating cultural 
appropriateness 
20,21,23,25-
27,33,41,43
. 
I B 94% 
Recommendation 5: 
Standardization and 
Transparency 
All collaborative paediatric 
research applications in the 
European Community should 
be filed in a standardized 
format and be submitted to a 
The current necessity of 
multiple ethics applications, the 
large variability in the 
submitting formats, and the 
lack of transparency of the 
reviewing process hinder 
collaborative paediatric 
research within the EU. A 
I B 100% 
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central electronic application 
portal. Following submission 
the review process should be 
transparent and electronically 
traceable. 
standardized submission and 
approval process through a 
central application portal as 
implemented in the EU portal 
for all clinical trials will 
overcome this barrier and 
facilitate research and care 
advancement 
21
. 
Recommendation 6: Central 
Competency 
The European Central Ethics 
Application Board should 
rapidly assess all multicentre 
applications for meeting 
formal EU-standards. All 
applications including 
timelines should be tracked in 
a central repository. The 
application should be 
transferred to the applicant's 
designated National Ethics 
Committee for Paediatric 
Research and Biobanking and 
undergo review including 
compliance with the specific 
ethical principles. After sign 
off, the other participating 
National Ethics Committees 
should rapidly adopt the 
decision. 
The standardization of 
application requirements and a 
unified primary, central review 
process overcomes barriers by 
simplifying the process while 
increasing the quality in 
accordance to the European 
regulation on clinical trials on 
medicinal products for human 
use (Clinical Trials 
Regulation)
21,44
. 
I B 100% 
Recommendation 7(1): 
Membership expertise 
Each National Ethics 
Committee for Paediatric 
Research and Biobanking 
should operate according to 
uniform standards.  
Membership: Each Committee 
has to include independent 
experts in paediatric research, 
lay members (non-
professionals including patient 
The ethics committee review of 
collaborative paediatric 
research studies and 
biobanking requires specific 
expertise reflected in its 
membership: Paediatricians 
should provide advice on 
clinical, ethical, and 
psychosocial aspects of 
research in minors. Lay 
members should offer support 
evaluating individual and 
societal impact of the proposed 
research. The review of genetic 
I A 94% 
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/ parent organizations or 
community advocates) and 
those with specific content 
expertise including genetics to 
review specific applications 
when appropriate. 
studies mandates an additional 
content expert for guidance 
20,21,25,44-46
. 
Recommendation 7(2): 
Support and Clarity 
Ethics application: Each 
Committee should provide 
direct assistance, clear 
instructions, and training 
courses to support the 
researcher.  
Instructions and applications 
should be written in a simple, 
universally understood 
language.  
Fees: Administrative fees 
should exclusively be charged 
in non-academic research; if 
charged, they should not 
constitute an obstacle. 
Administrative support, training 
opportunities, and transparent, 
simple instructions will help 
facilitate the paediatric 
research ethics application. For 
investigator initiated, non-
commercial studies fees should 
not constitute a barrier to 
research. Fees should be set 
solely on the basis of cost 
recovery principles and be 
reduced or waived when 
appropriate 
20,21,28,47
. 
I A 
 
 
 
 
 
 
 
 
  
100% 
Paediatric Principles 
Recommendation 8: 
Subsidiarity 
A study that will produce 
generalizable results across all 
age groups should 
preferentially be performed in 
adults. 
Adults should be primarily 
included in research studies, 
since they are capable of giving 
truly informed consent. 
Children are a vulnerable 
population and need 
protection. Generalizable 
research has to be conducted in 
adults capable to consent 
20,22,23,25,27,33,41,42,44
. 
I A 88% 
Recommendation 9: 
Paediatric Rule 
Children should receive special 
Children are a vulnerable 
population. The potential risks 
including privacy risks related 
to genetic information, physical 
I A 100% 
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protection when included in 
data and biobank studies.  
and emotional harms, and 
disrespect of values should be 
minimized during sample 
collection and the duration of 
the research study. Justification 
is required when inviting 
vulnerable individuals to serve 
as research subjects, the risk 
should be minimal and the 
means of protecting rights and 
welfare must be strictly applied 
20,22,23,25,27,33,42,43,45,48
. 
Consent in Paediatric Research 
Recommendation 10: 
Integration of Minors 
Voluntary and age-
appropriate informed 
consent/assent has to be 
obtained from legal guardians 
and/or minors as appropriate 
according to the international 
guidelines (ICH, WHO, others) 
before paediatric data and 
biospecimen can be collected 
and used for research.  Minors 
should be integrated into the 
process of consent and those 
capable of forming an opinion 
and assessing the information 
given, should be asked to give 
assent or consent, as 
appropriate. 
Children have the right to be 
included in research and 
benefit from research 
discoveries. All research 
mandates voluntary, informed 
consent given by a competent 
individual, who has received 
the necessary information and 
has adequately understood the 
information. The decision to 
participate has to be reached 
without coercion, undue 
influence or intimidation. 
Informed consent embodies the 
individual's freedom of choice 
and respects the individual's 
autonomy. Legal guardians may 
serve as proxies for minors, 
who do not have full capacity, 
in the consent process; children 
should be integrated in the 
consent process and their 
opinion and views have to be 
respected 
12,20,22,23,25-
27,31,33,43,46,49-53
. 
I A 100% 
Recommendation 11: 
Enabling Informed Consent 
All information given to the 
child and the legal guardian 
should be age appropriate, 
The process of consenting must 
not be simply a ritual recitation 
of the contents of a written 
document. The information 
must be conveyed in language 
that suits the individual's level 
I B 100% 
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written, and presented by a 
competent person in the 
country’s official language. 
Paediatric participants and 
legal guardians should be 
granted appropriate time to 
make and reconsider their 
decision. Withdrawal of 
consent should be possible at 
any time of the study. 
of understanding. Parents/legal 
guardians and children must be 
given time and opportunity for 
discussion to make the decision 
without any pressure to 
consent. Participants should be 
informed that consent/assent 
can be withdrawn at any time.  
Exercising the right to withdraw 
cannot entail consequences in 
medical care services 
20,22,23,25-
27,43,46,48,49,52,54
. 
Recommendation 12: Scope 
of Consent 
The scope of consent should 
preferably be broad. Broad 
consent should include future 
research opportunities, 
possibility to share samples 
and data with national and/or 
international research 
partners.  Broad consent 
should include the possibility 
to re-contact participants. 
Consent forms need to be 
internationally harmonized to 
ensure international research 
projects. Consent forms have 
to include the possibility for 
specimen shipment and data 
transfer. Consenting should 
include the opportunity to opt 
out of certain aspects of 
research. 
Broad consent reduces the 
burden for participants as it 
avoids the need for re-sampling 
of biospecimen and re-
collection of data in addition to 
the need for re-consenting. 
Broad consent avoids the need 
to re-contact and re-consent 
participants, which may 
represent a significant barrier 
to conducting research. It 
allows for novel research to be 
conducted that had not been 
conceptualized at the time of 
the initial study. Permission for 
data and specimen transfer 
should be included in the 
harmonized consent forms.  A 
governance specification and 
an opt-out option have to be 
included enabling participants 
to limit the use of their 
specimens and data to distinct 
research questions 
22,26,27,30,37,43,45,48,55-57
. 
I B 100% 
Recommendation 13: Re-
consenting  
Paediatric participants that 
have previously only given 
assent should be re-contacted 
for consent to an ongoing 
study when reaching legal age. 
At time of reaching legal age 
the formal legal status of the 
participant changes. This 
mandates obtaining re-consent 
since the initial consent was not 
obtained from the minor and 
therefore has limited temporal 
I A 88% 
Page 29 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 24
Researchers should make 
considerable effort to re-
contact participants for 
further use of data and 
samples. The ethics 
committee should evaluate 
the option of further use of 
data and sample, if 
participants are not reachable. 
scope. Allowing the competent 
child a right to withdraw 
materials given into the 
biobank by proxy consent is 
consistent with the idea of a 
child's "right to an open 
future”, which states that 
choices made for a child when 
being a minor should not 
preclude the right to make 
decisions when reaching legal 
age. The former minor has now 
full autonomy and is now able 
to oversee the dimension of the 
research and can give informed 
consent for ongoing research 
generated from databases and 
biobanks. In case the 
participant cannot be reached, 
the researcher should seek 
advice from the ethics 
committee for further use of 
data and samples 
18,21,22,26,27,48,58,59
. 
Recommendation 14: 
Incidental Findings 
Researchers should partner 
with expert health care 
providers and inform patients 
and legal guardians about 
clinically relevant results. 
Participant’s refusal to be 
informed about clinically 
relevant results represents an 
exclusion criterion. 
In adults the principle of 
autonomy and the individual 
right “to know or not to know” 
defines the extent to which 
researchers should inform 
participants including children 
and their legal guardians about 
clinically relevant results 
detected in research studies. In 
paediatric studies, the proxy 
consent does not cover this 
decision.  Here, researchers 
have a moral duty to inform 
minor participants and their 
legal guardians about clinically 
relevant results that mandate 
action including research result 
and incidental findings. Findings 
should be communicated by an 
expert clinician 
20,22,23,25,27-
I B 100% 
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29,33,42,43,60
. 
Paediatric Data and Biobanks: Operational Principles 
Recommendation 15: 
Organizational Framework   
The organizational 
frameworks for collaborative 
paediatric data- and biobanks 
must include a governance 
structure. Terms of 
transparency, fair access to 
data and samples including 
ownership, authorship of 
research publications, 
payment, and reciprocity of 
sample sharing should be 
defined. Principles of 
interoperability should be 
followed. Data- and /or 
material transfer agreements 
should be elaborated and 
signed between research 
partners. Researchers should 
develop a long-term plan for 
sustainability. Biobanks should 
be captured in a central 
electronic tracking system. 
An organizational framework 
prevents ethical and legal 
conflicts, enables long-term 
collaborations between 
participating researchers. The 
development and endorsement 
of standards enables higher 
research interoperability. 
Transparency of the framework 
and its policies is necessary for 
biobanks in all levels. 
Standardized design and 
harmonization of data fields 
enables interoperability 
between biobanks.  A 
governance structure and a 
long-term sustainability plan 
will ensure public trust and long 
benefits. A central registry for 
European biobanks will not only 
reduce the burden of repeated 
sample collection but also helps 
to use existing resources in the 
most efficient way 
3,21,26-
28,33,37,43,57,61
. 
I B 100% 
Recommendation 16: 
Sampling 
Non-invasive sampling 
approaches should be 
preferentially used in children. 
Standard operating 
procedures (SOPs) of 
paediatric sample collection, 
processing, pre-analytic 
handling, and shipment should 
be defined and observed to 
ensure high quality specimen 
handling. 
The Paediatric Rule mandates 
minimal invasive sampling, 
which may result in small 
quantities of biospecimen and 
may require designated, 
harmonized SOPs. Processing of 
paediatric biospecimen and 
capture of paediatric data 
samples should include 
necessary measures to ensure 
the accuracy, reliability, quality, 
and security 
20,25,27,28,41,46,57,61,62
. 
I B 100%) 
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Sharing of Data and Samples     
Recommendation 17: Data 
Harmonization 
Collaborative databanks 
should built on available 
instruments of data 
harmonization, standardized 
access to data, define 
measures of high data quality 
including data dictionaries, 
and regulate data transfer. 
Harmonization of data fosters 
the interoperability of systems 
and facilitates the exchange of 
scientific data. High quality 
standards enable the possibility 
of international collaborative 
research with health related 
benefits for future generations. 
Quality assurance measures 
should be implemented, 
including conditions to ensure 
appropriate security and 
confidentiality during 
establishment of the collection, 
storage, use and, where 
appropriate, transfer of data 
and materials 
3,26-28,30,33,57,61,63
. 
I A 100% 
Recommendation 18: Data 
Protection  
Researchers should 
implement a state-of-the-art 
data and sample protection 
system. Secure coding of data 
and samples should ensure 
confidentiality while enabling 
withdrawal of consent, re-
consenting, and notification of 
clinically relevant results. 
Secure data-sample linkage 
systems should be 
established. 
Researchers are custodians of 
personal data and biospecimen. 
They are responsible for 
establishing a system of secure 
safeguards for privacy, 
confidentiality, and legitimate 
access.  While using anonymous 
data and samples is the best 
way to protect personal 
information, it is not feasible in 
paediatric research as it limits 
the researchers’ ability to act 
on withdrawal of consent, the 
need for re-consenting and the 
detection, and notification of 
clinically relevant results. All 
data handling has to follow the 
standards of the EU General 
Data Protection Regulation 
20,26,27,30,33,37,46,57,61,63
. 
I A 100% 
Recommendation 19: 
Standardization of Transfer 
Specimen transfer should 
include standardized 
packaging and labelling, 
Standardization of shipment in 
accordance with international 
regulations and laws including 
all accompanying documents 
ensures a safe and confidential 
transfer of biological materials 
I B 100% 
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accompanying transfer 
documentation, customs 
regulations, and sample 
tracking. The consent form 
must include the agreement 
to share data and samples. 
across borders.  A documented 
agreement between the sender 
of the biological materials and 
the recipient should be signed. 
The patient's agreement of data 
and specimen transfer has to be 
obtained and shared 
26-28,35,37
. 
Commercialization and Third Party Access 
Recommendation 20: Fees 
and Incentives 
Biobanks should enable 
research to improve medical 
knowledge. Provision of data 
and samples should be free; 
shipment and processing costs 
should be covered by the 
requesting research team. 
Participants or their parents 
should not receive payment. 
Responsible sharing of 
biospecimen and data should 
be guided by the principle of 
the “Universal Declaration of 
Human Rights, 1948”, which 
grants every individual the right 
to „share in scientific 
advancement and its benefits“.  
In fact, the Council of Europe 
states that sharing of all 
knowledge and distribution of 
materials will be obligatory.  
Collaborative paediatric 
research aims to maximize 
discoveries by sharing of 
resources, data, and samples. 
Financial incentives should be 
avoided. The operators of data 
and biobanks must ensure that 
any stratified access or fee 
policies are fair, transparent, 
and do not inhibit research 
20,25,26,28,33,37,39,61,64,65
. 
I A 100% 
Recommendation 21: Third 
Parties 
Researchers have to obtain 
ethics approval before giving 
patient data or sample access 
to third parties. Continuous 
education of the public about 
biobanks is important to 
retain public trust in research. 
The autonomy principle 
mandates that a patient has to 
give consent to any sharing of 
data and biospecimen. A 
researcher therefore should not 
share any data or specimens 
with third parties unless the 
patient permits such 
submission and an ethics 
approval was obtained. The 
most important prerequisite for 
successful biobank related 
research is ensuring the public 
I A 100% 
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trust. This can be achieved 
through continuous education 
of people and protection of 
privacy 
18,20,25,26,30,33,39,43,45
. 
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Abstract  
Objectives: Innovative research in childhood rheumatic diseases mandates international 
collaborations. However, researchers struggle with significant regulatory heterogeneity; an 
enabling EU-wide framework is missing. The aims of the study were to systematically review 
the evidence for best practice and to establish recommendations for collaborative research. 
Methods: The Paediatric Rheumatology European SHARE project enabled a scoping review 
and expert discussion, which then informed a the systematic literature review. Published 
evidence was synthesized; recommendations were drafted. An iterative review process and 
consultations with Ethics Committees and European experts for ethical and legal aspects of 
paediatric research refined the recommendations. SHARE experts and patient 
representatives vetted the proposed recommendations at a consensus meeting using 
Nominal Group Technique. Agreement of 80% was mandatory for inclusion.  
Results: The systematic literature review returned 1319 records.  A total of 223 full-text 
publications plus 22 international normative documents were reviewed; 85 publications and 
16 normative documents were included. A total of 21 recommendations were established 
including general principles (1-3), ethics (4-7), paediatric principles (8 and 9), consent to 
paediatric research (10 -14), paediatric data- and biobanks (15 and 16), sharing of data and 
samples (17 - 19), and commercialization and third parties (20 and 21). The refined 
recommendations resulted in an agreement of >80% for all recommendations.  
Conclusions: The SHARE initiative established the first recommendations for Paediatric 
Rheumatology collaborative research across borders in Europe. These provide strong 
support for an urgently needed European framework and evidence-based guidance for its 
implementation. Such changes will promote research in children with rheumatic diseases.  
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Introduction  
Paediatric rheumatic diseases are rare and often devastating; advancing knowledge and 
improving care and outcomes of affected children mandates research collaborations across 
national borders 
1-3
. Across Europe, several national innovative research teams have made 
substantial contributions to developing clinical tools, biomarkers, and imaging strategies for 
children with rheumatic diseases. Their evaluation and implementation mandates 
international patient cohorts and research partnerships given that some paediatric 
rheumatic diseases have incidences as low as one per million. 
The European community strongly encourages collaborative international research and 
funded the “Single Hub and Access point for paediatric Rheumatology in Europe (SHARE)" 
initiative, which aims to optimize care and research for children with rheumatic diseases 
across Europe
4-8
.  A key task was the identification of barriers between nations for 
collaborative Paediatric Rheumatology research. Currently, researchers funded to conduct 
important studies struggle with the substantial heterogeneity within and across European 
countries in all areas of rare diseases research. These include ethics approval process, 
consent and assent, formal frameworks for data and sample collection and sharing, and 
aspects of third party data and sample access. Currently there is no EU-wide framework 
facilitating the conduct of collaborative rare diseases research
9
. 
Therefore the aims of the study were to synthesize the evidence for best practice in 
paediatric rheumatic diseases research and to develop recommendations to enable research 
collaborations including data- and biobanking across Europe. 
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Methods 
Scoping review and expert consultation 
A scoping review focussing on collaborative paediatric research was conducted identifying 
key themes. In addition, major stakeholders including ethics committee members, European 
Paediatric Rheumatology researchers, and patients with rare diseases were asked to provide 
input regarding their perspectives on research and its barriers and challenges using 
structured interviews by surveys, phone, and in-person. The group identified key themes and 
constructed an evaluative framework including a modification of the evidence ranking 
system supported by the Cochrane group (Figure 1).  
 
Systematic review  
Search strategy and selection criteria 
A systematic literature review anchored in the identified key themes was performed and 
reported according to the standards of the “Preferred reporting items for systematic review 
and meta-analysis protocols (PRISMA)” guidelines
10,11
. This systematic search of the 
literature aimed to identify studies of focussing on all aspects of paediatric research in 
Europe. These were specified in MESH terms and subheadings including data collection, 
ethics, biological specimen banks, confidentiality, informed consent by minors, specimen 
handling, jurisprudence, quality improvement, legislation, classification, methods, 
organization, administration, standards, and instrumentation. The search was performed in 
the electronic databases PubMed and Web of Science on 14th May 2014. The search was 
limited to articles published in English and focussing on children and adolescents (ages 0-18 
years); the search period was set between January 1989 and April 2014, guided by the 
publication date of the United Nation's Convention on the Rights of the Child
12
. In addition 
to the electronic literature search, a manual review of the references of all relevant 
publications and international and European normative documents was conducted. Articles 
were excluded, if the content was not related to children and adolescents, it did not apply to 
the European context, or to any aspect of collaborative paediatric research.  
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Data extraction and validity assessment  
The remaining full-text articles were reviewed by a panel of experts, graded by two 
independent researchers, and reconciled by a third using predefined scoring instruments for 
the different study and publication types as appropriate
13,14
. The following variables were 
abstracted: reference, year of publication, authors, country of focus, and contribution to the 
themes. Levels of evidence and strength of recommendations were determined using an 
adjusted framework for grading scientific evidence in order to account for normative 
documents including declarations, regulations, guidelines, and legislative documents
15
. 
 
Development and refinement of recommendations 
Grouped by distinct themes, the evidence was synthesized; additional domains were 
developed including public opinion on paediatric research, guidelines, and jurisdiction. 
Recommendations were drafted. In-depth discussion, iterative reviews, and adjustments of 
the recommendations were completed with ethics committee staff members and 
international content experts in paediatric ethics (KH) and legislation (DS). The draft version 
of the recommendations was sent to all SHARE experts in an online survey format for review 
and revision. All suggestions were integrated and additional recommendations were drafted; 
the revised documents were re-distributed to the experts for review and evaluation of 
agreement.  
 
Consensus meeting 
The proposed and reviewed recommendations were presented to the SHARE expert 
committee and patient representatives during a face-to-face consensus meeting in Rome, 
Italy, and discussed in-depth using Nominal Group Technique
16
. Recommendations were 
accepted by reaching agreement above 80%.  
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Results 
Scoping review and expert consultation  
The key themes of collaborative paediatric research and biobanking in Paediatric 
Rheumatology were identified. These included ethics, legislation, consent, scope of consent, 
confidentiality, anonymisation, sample and data collection, handling, and storage. These 
were translated into search terms to inform the evidence synthesis.  
 
Systematic literature review  
The initial search returned 7347 records, of which 6503 had to be excluded. Ultimately, 1319 
publications including 844 from PubMed and 475 papers from the Web of Science Core 
Collection were identified. After removing 31 duplicates, a total of 1288 records were 
manually reviewed for title and abstract excluding 1065. Full-text assessment of 223 papers 
resulted in exclusion of 161. A total of 62 publications plus an additional 23 identified by 
targeted hand-search from references resulted in 85 papers to be included (see Table S1). A 
full-text review of 22 normative documents yielded 16 relevant documents including three 
international declarations, five guidelines, four European legislative documents, and four 
recommendations (see Table S2 and Figure 2).  
 
Data extraction and validity assessment  
Among the 85 retained publications three publications were systematic reviews, defined as 
evidence level II a (none were II b), 15 were non-systematic reviews (evidence level III), 24 
cross-sectional studies (level IV b), 16 narrative reviews, and 27 expert opinions (evidence 
level V b). All 16 normative documents were found to be evidence level I. 
 
Development and refinement of recommendations 
Evidence was translated into draft recommendations. Themes identified were the following: 
guiding principles, ethics, paediatric principles, consent to paediatric research, paediatric 
data- and biobanks: operational principles, sharing of data and samples, commercialization, 
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and third party access. In an iterative process draft recommendations were reviewed and 
refined by consulting experts and the European SHARE panel.  
 
Consensus meeting 
A total of 21 recommendations were drafted, grouped into the domains of Guiding Principles 
(Recommendation 1 - 3), Ethics (Recommendation 4 -7), Paediatric Principles 
(Recommendation 8 and 9), Consent in Paediatric Research (Recommendation 10 - 14), 
Paediatric Data- and Biobanks: Operational Principles (Recommendation 15 and 16), Sharing 
of Data and Samples (Recommendation 17 - 19), and Commercialization and Third Party 
Access (Recommendation 20 and 21).  Face-to-face discussion further refined all 
recommendations resulting in an agreement of >80% for all at the final consensus 
conference. 
 
Recommendations  
Guiding Principles  
The 2006 European Regulation No 1901/2006 of the European Parliament and of the Council 
on Medicinal Products for Paediatric Use (Paediatric Regulation) for the first time mandated 
the development and submission of an investigation plan for children at early stages of drug 
development in Europe
17
. The regulation emphasized the specific needs of children and 
aimed to end their status as “therapeutic orphans”
17,18
. In 2009, the EU Council published an 
action plan for rare diseases strongly encouraging Europe-wide collaborative studies 
including establishing sustainable infrastructure such as registries and biobanks
2
.  The plan 
mandated support for research training and sharing of tools and expertise across Europe. It 
emphasized the need for the development of European guidelines and recommendations for 
evaluation and treatment of rare diseases
2
. The 7
th
 Framework Program of the EU for 
Research 1982/2006/EC, Technological Development and Demonstration Activities 
encouraged the investigator-driven development of collaborative research networks, further 
building of European research capacity, and sharing of data and specimens
19
. In 2013, the 
Biobanks and Biomolecular Resources European Research Infrastructure Consortium 
(BBMRI-ERIC) was charged with the development of a the Europe-wide research 
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infrastructure of biobanks
3
.  These general principles for collaborative paediatric research in 
Europe are captured in Recommendations 1 - 3 (Table 1). 
 
Ethics  
The 2008 International Ethical Guidelines for Epidemiological Studies prepared by the 
Council for International Organizations of Medical Sciences (CIOMS) and the World Health 
Organization (WHO) defined that all proposals to conduct research in human subjects must 
be submitted for r view of scientific merit and ethical acceptability to review committees. It 
specified that ethics committees should establish working rules regarding frequency of 
meetings, a quorum of members, decision-making procedures, and review of decisions. The 
guidelines specified that the committee should provide its rules to prospective 
investigators
20
. In 2014, the Regulation 536/2014 of the European Parliament and of the 
Council on Clinical Trials on Medicinal Products for Human Use (Clinical Trials Regulation) 
aimed to simplify and harmonize the administrative provisions of clinical trials in Europe
21
. It 
mandated the submission of a single application dossier to all the Member States concerned 
through a single submission portal. The regulation defined that member states were to 
determine the appropriate body to be involved in the assessment of the application and to 
organize the involvement of ethics committees within a specific timeline of the trial. It 
further specified that the designated ethics committee had to have appropriate expertise 
and membership to review the application
21
. Concepts of centralization, transparency, and 
organizational expertise of ethics committees are captured in Recommendations 4 - 7 (Table 
1). 
 
Paediatric Principles  
The 1989 Convention on the Rights of the Child defined principles founded on respect for 
the dignity and worth of each child, regardless of race, colour, gender, language, religion, 
opinions, origins, wealth, birth status, or ability
12
. The Convention aimed to protect children, 
to help secure their basic needs, and to enhance the possibility of reaching their best 
potential
12,22
. The World Medical Association statement of the Declaration of Helsinki of 
Ethical Principles for Medical Research Involving Human Subjects emphasised the 
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importance of special protection of vulnerable populations including children
23
. It specified 
that medical research with a vulnerable group such as children is only justified, if the 
research is responsive to the health needs and priorities and cannot be carried out in a non-
vulnerable group
23
. The benefit of participating in a research study has to outweigh the 
potential risk
21
. The principle of minimal risk is a virtual standard for research in children
24
. 
Minimal risk is considered a risk that is similar to the child’s risk in everyday life
22
 and should 
not be greater than the risk attached to a routine medical examination
25
. The 2014 Clinical 
Trials Regulation specified that research in children should be performed out of necessity 
and a presumed benefit for the minor directly or for children with the same condition
21,24
. 
The principles of subsidiarity and the paediatric rule are captured in the Recommendations 8 
and 9 (Table 1). 
 
Consent in Paediatric Research  
The 2008 CIOMS/WHO International Ethical Guidelines for Epidemiological Studies 
mandated that before undertaking research involving children the investigator must ensure 
that a parent or legal representative of each child has given permission. In addition, the 
agreement of each child (assent) has to be obtained to the extent of the child’s capability
20
. 
It demands that the investigator must convey the information in language suitable to the 
individual child’s level of understanding and abilities. The consent/assent process has to 
include provision of sufficient time and opportunities for clarification
20
. The 2009 
Organization for Economic Co-Operation and Development (OECD) Guidelines on Human 
Biobanks and Genetic Research Databases suggested participants should be given a range of 
possible scopes of consent to choose from including broad consent to minimize potential risk 
of harm. In addition, the participant’s right to withdraw from the research at any time has to 
be emphasized
26
.  The 2016 Recommendation CM/Rec (2016)6 of the Committee of 
Ministers to Member States on Research on Biological Materials of Human Origin defined 
that re-consent has to be obtained, when a person attains capacity to consent
27
. It also 
mandated that clear policies should be in place ensuring communication of concerning 
findings that are relevant for the health of the persons – the so-called incidental findings
27
.  
While in adults based on the UNESCO International Declaration on Human Genetic Data the 
right of an individual to decide whether or not to be informed of the results of genetic 
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examinations should be respected
28
, the importance to act in the best interest of minors 
may override this right in children
29
.  Refusal to be informed about incidental findings 
therefore represents a barrier for the participation of minors in Refusal to be informed 
about clinically relevant findings therefore represents a barrier for the participation of 
minors in research; parents cannot make the choice for their children not be informed about 
clinically relevant resultsresearch
29
. The concepts of consent/assent, withdrawal of consent, 
re-consenting, and incidental findings in paediatric research are captured in the 
Recommendations 10-14 (Table 1). 
 
Paediatric Data- and Biobanks 
The 2009 OECD Guidelines on Human Biobanks and Genetic Research Databases mandated 
that data- and biobanks should be governed by principles of transparency and accountability 
including a clear formulation of governance structure and responsibility for its 
management
26
. It also demanded that operators should have protocols and processes in 
place to protect participants’ personal and medical information.  The 2013 European 
Commission Implementing Decision of the Biobanking and Biomolecular Resources European 
Research Infrastructure Consortium(BBMRI-ERIC) was charged with establishing and 
operating a pan-European research infrastructure including improved interoperability of 
data- and biobanks
3
.  It also mandated the implementation of quality management including 
standardized procedures and best practices. The 2016 Recommendation CM/Rec (2016)6 of 
the Committee of Ministers to Member States on Research on Biological Materials of Human 
Origin demanded safeguards to be put in place to ensure confidentiality at the time of 
collection, storage, and transfer of biological materials
27
 . The 2016 Regulation 2016/679 of 
the European Parliament and the Council, the General Data Protection Regulation, 
mandated special protection of information originating from children
30
. The concepts of 
organisation and conduct of paediatric data- and biobanks are captured in the 
Recommendations 15-21 (Table 1). 
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Discussion 
The SHARE initiative developed the first European recommendations for collaborative, 
paediatric research including biobanking for children with rheumatic diseases. A 
comprehensive systematic literature review including European legislative documents and 
an iterative consensus procedure was completed. A total of 21 recommendations were 
developed, refined, agreed on by expert clinicians in childhood disease, methodologists, 
paediatric researchers, and content experts of paediatric ethics and legislation, partnered 
with patient representatives. These recommendations will provide a robust framework for 
collaborative European research in rare childhood diseases in multicentre studies and the 
European Reference Networks (ERN) that are currently being created.  
Transformative European research in childhood diseases increasingly requires Europe-wide 
collaborations. This is particularly important for rare diseases such as the entire spectrum of 
rheumatic diseases of childhood. The proposed framework of recommendations includes 
concepts of guidance and support for collaborative research teams. It advocates increasing 
the competency and transparency of a proposed centralized ethics committee review 
processes of childhood rare diseases, as successfully modelled by the 2014 European 
Regulation on Clinical Trials 
21
. It provides evidence-based, structured guidance for all 
aspects of consent, data harmonization, and standardization of bio-specimen SOPs across 
Europe. This framework is the first of its kind. It was built upon a comprehensive review of 
published evidence, guidance of European leaders in ethics and law, and practical 
experience of leading paediatric researchers, and expert clinicians. Normative documents 
including ratified European laws and international declarations were reviewed and served as 
high-level evidence, an approach common to the area of ethics research, yet unfamiliar to 
medical researcher. Most iImportantly, the process it has integrated the perspective of 
families living with childhood rare diseases. While being constructed in the context of a the 
European Union funded research grant for paediatric rheumatic diseases, it is thought that it 
is likely to be transferrable to all collaborative childhood rare diseases research.  
Research in children poses a the unique challenge and requires the inclusion of specific 
considerations. Most importantly, children have the right of designated paediatric research 
to advance the understanding of childhood diseases and development of best therapies
31
. 
This right has to be balanced with the societal mandate to protect children from harm
12
. The 
Page 51 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 15
recommendations aim to strike this balance by including principles such as subsidiarity, the 
paediatric rule, the protection of minors, and the minimization of burden
22
. Special 
considerations were given to the integration of minors in the consenting process
32
. While 
consent is obtained from the legal guardian, minors have to be appropriately informed and 
have to have a voice in the decision making process
33
. It was emphasised that consent in 
paediatric research should be broad to minimize harm and that re-consenting is mandatory 
when minors reach legal age
27
. The possibility of clinically relevant, actionable incidental 
findings has to be taken into account
34
. Distinctly different from research in adults, refusal to 
be informed about these findings has to be considered an exclusion criterion for paediatric 
research study participation
29
.  
There are several limitations to the study and its results. The key limitation is the 
generalizability beyond Europe. Published literature and normative documents applicable to 
the European context only informed the recommendation development. The transferability 
into another cultural context such as North or South America has to be explored. When 
aiming so, the literature search and evidence synthesis would have to include publications 
and most importantly normative documents beyond Europe. In addition, The the expert 
team had a content and method focus on childhood rheumatic diseases. In order to increase 
the generalizability care researchers, patients and families with a spectrum of other 
conditions including common and rare, acute and chronic illnesses would need to be part of 
the process. The transferability to other childhood diseases cshould then be tested; 
recommendations may require additional specifications when applied to a different disease 
context. However, it appears that principles captured in the proposed set of 
recommendations are widely generalizable across childhood diseases.  
 The SHARE initiative enabled the development of the first recommendations for Paediatric 
Rheumatology collaborative research including data- and biobanking and sharing across 
borders. These recommendations provide strong support for an urgently needed European 
legislative framework and evidence-based guidance for its implementation. Children with 
rheumatic conditions and the many others suffering from rare diseases should no longer be 
left behind when life-changing research discoveries can be made. 
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Figure legends 
Figure 1 
Modified hierarchy of evidence pyramid for inclusion of normative documents  
Legend: The pyramid depicting the hierarchy of evidence was modified with guidance of the 
Cochrane collaboration to enable the inclusion of all available scientific evidence and 
international normative documents in the systematic review.  
 
Figure 2 
Literature selection flow chart  
Legend: The search included the following MESH-terms: data collection, ethics, biological 
specimen banks, confidentiality, informed consent by minors, specimen handling, quality 
improvement, and jurisprudence. In addition, the following subheadings were used: 
legislation, classification, methods, organization, administration, standards, and 
instrumentation. The search was limited to literature relevant to the paediatric age group (0 
to 18 years of age) and to Europe. 
 
Search strategy  
((((((( "Data Collection/ethics"[Mesh] OR "Data Collection/legislation and 
jurisprudence"[Mesh] ))) OR (((((( "Ethics/classification"[Mesh] OR "Ethics/ethics"[Mesh] OR 
"Ethics/legislation and jurisprudence"[Mesh] OR "Ethics/methods"[Mesh] OR 
"Ethics/organization and administration"[Mesh] OR "Ethics/standards"[Mesh] ))) OR ethics)) 
AND (( "Biological Specimen Banks/classification"[Mesh] OR "Biological Specimen 
Banks/ethics"[Mesh] OR "Biological Specimen Banks/instrumentation"[Mesh] OR "Biological 
Specimen Banks/legislation and jurisprudence"[Mesh] OR "Biological Specimen 
Banks/methods"[Mesh] OR "Biological Specimen Banks/organization and 
administration"[Mesh] OR "Biological Specimen Banks/standards"[Mesh] )))) OR (((( 
"Confidentiality/ethics"[Mesh] OR "Confidentiality/legislation and jurisprudence"[Mesh] OR 
"Confidentiality/organization and administration"[Mesh] OR 
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"Confidentiality/standards"[Mesh] ))) AND (( "Biological Specimen 
Banks/classification"[Mesh] OR "Biological Specimen Banks/ethics"[Mesh] OR "Biological 
Specimen Banks/instrumentation"[Mesh] OR "Biological Specimen Banks/legislation and 
jurisprudence"[Mesh] OR "Biological Specimen Banks/methods"[Mesh] OR "Biological 
Specimen Banks/organization and administration"[Mesh] OR "Biological Specimen 
Banks/standards"[Mesh] )))) OR (( "Informed Consent By Minors/ethics"[Mesh] OR 
"Informed Consent By Minors/legislation and jurisprudence"[Mesh] OR "Informed Consent 
By Minors/organization and administration"[Mesh] OR "Informed Consent By 
Minors/standards"[Mesh] ))) OR ((((((( "Specimen Handling/ethics"[Mesh] OR "Specimen 
Handling/legislation and jurisprudence"[Mesh] ))) OR (("Specimen 
Handling/standards"[Majr]) AND "Quality Improvement"[Mesh])) OR (("Specimen 
Handling"[Mesh]) AND "Ethics"[Mesh])) OR (("Jurisprudence"[Majr]) AND "Specimen 
Handling"[Majr])) OR (((("Specimen Handling"[Majr]) And ("legislation and jurisprudence" 
[Subheading]))) OR (("Specimen Handling"[Majr]) AND "ethics" [Subheading]))))) OR (( "Data 
Collection/ethics"[Majr:NoExp] OR "Data Collection/legislation and 
jurisprudence"[Majr:NoExp] )) 
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Table 1 
Recommendations for collaborative paediatric research including biobanking in Europe 
 
Text of recommendations  Justification Evidence 
level 
Strength of 
recommen-
dation 
Agree-
ment 
Guiding Principles 
Recommendation 1: 
Advancing Care and Discovery  
Research in children should be 
supported including 
international, multi-centre 
data collection and banking 
and transfer of biological 
specimens. Collaboration 
enables discovery in paediatric 
diseases and care 
advancement for children, in 
particular for those with rare 
diseases. 
Discovery and care 
advancement in paediatric 
diseases requires collaborative 
longitudinal research projects 
of international scale in order 
to include sufficient numbers of 
participants and generate 
robust scientific data. The 
international collaborative 
collection, storage, and sharing 
of human biological material 
and associated clinical 
information reduce the overall 
burden of sampling for patients 
and researchers enabling 
sustained, high-quality 
research
2,17,18,22,33,35
. 
I B 100% 
Recommendation 2: Enabling 
Support 
Paediatric researchers should 
be offered research training 
opportunities, access to 
mentorship and guidance, 
protected time, and financial 
support to conduct paediatric 
research. Institutional 
resources for research 
protocol development, 
translation services, ethics 
submission, and research 
conduct should be made 
available. 
The complexity of collaborative 
paediatric diseases research 
and the heterogeneity of rules, 
regulations, and processes 
within and across European 
countries mandate researchers 
to develop distinct skill sets and 
content knowledge. Focused, 
comprehensive training, 
institutional assistance, and 
guidance partnered with 
financial and other support will 
enable researchers to 
overcome the disproportionally 
challenging barriers towards 
successful multi-national 
paediatric diseases research 
requiring sample and data 
I B 100% 
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collection 
2,20,28,36-38
. 
Recommendation 3: 
Supportive Legislative 
Framework 
A supportive legislative 
framework for international 
collaborating biobanks is 
lacking. A framework (WHO, 
ICH, EMA, FDA, other) should 
be implemented to overcome 
legal and ethical barriers in 
international research. An 
international binding 
shipment and custom 
agreement for biological 
samples should be 
established. 
The regulatory requirements 
for paediatric biobanking vary 
significantly between European 
countries. This dramatically 
complicates the implementing 
of international paediatric 
diseases biobanks. A unified 
European framework should be 
developed and implemented in 
order to facilitate the 
international sharing of 
precious paediatric 
biospecimen and enable life-
saving discoveries 
3,24,33,37,39-42
. 
II B 100% 
Ethics 
Recommendation 4: 
Centralized Ethics  
All international collaborative 
paediatric research should be 
reviewed by central European 
Ethics Committees. All 
auxiliary studies require 
additional review and 
approval. The review has to 
capture all ethical principles 
including privacy rights. 
Designated and highly qualified, 
independent, and centralized 
Ethics Committees should serve 
as Competent Authority for 
paediatric research. 
Subsequent, auxiliary studies 
should be reviewed by the 
same committee. The resulting 
single ethics vote captures the 
highest ethical principles and 
privacy standards. 
Subsequently National Ethics 
Committee reviews are solely 
tasked with evaluating cultural 
appropriateness 
20,21,23,25-
27,33,41,43
. 
I B 94% 
Recommendation 5: 
Standardization and 
Transparency 
All collaborative paediatric 
research applications in the 
European Community should 
be filed in a standardized 
format and be submitted to a 
The current necessity of 
multiple ethics applications, the 
large variability in the 
submitting formats, and the 
lack of transparency of the 
reviewing process hinder 
collaborative paediatric 
research within the EU. A 
I B 100% 
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central electronic application 
portal. Following submission 
the review process should be 
transparent and electronically 
traceable. 
standardized submission and 
approval process through a 
central application portal as 
implemented in the EU portal 
for all clinical trials will 
overcome this barrier and 
facilitate research and care 
advancement 
21
. 
Recommendation 6: Central 
Competency 
The European Central Ethics 
Application Board should 
rapidly assess all multicentre 
applications for meeting 
formal EU-standards. All 
applications including 
timelines should be tracked in 
a central repository. The 
application should be 
transferred to the applicant's 
designated National Ethics 
Committee for Paediatric 
Research and Biobanking and 
undergo review including 
compliance with the specific 
ethical principles. After sign 
off, the other participating 
National Ethics Committees 
should rapidly adopt the 
decision. 
The standardization of 
application requirements and a 
unified primary, central review 
process overcomes barriers by 
simplifying the process while 
increasing the quality in 
accordance to the European 
regulation on clinical trials on 
medicinal products for human 
use (Clinical Trials 
Regulation)
21,44
. 
I B 100% 
Recommendation 7(1): 
Membership expertise 
Each National Ethics 
Committee for Paediatric 
Research and Biobanking 
should operate according to 
uniform standards.  
Membership: Each Committee 
has to include independent 
experts in paediatric research, 
lay members (non-
professionals including patient 
The ethics committee review of 
collaborative paediatric 
research studies and 
biobanking requires specific 
expertise reflected in its 
membership: Paediatricians 
should provide advice on 
clinical, ethical, and 
psychosocial aspects of 
research in minors. Lay 
members should offer support 
evaluating individual and 
societal impact of the proposed 
research. The review of genetic 
I A 94% 
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/ parent organizations or 
community advocates) and 
those with specific content 
expertise including genetics to 
review specific applications 
when appropriate. 
studies mandates an additional 
content expert for guidance 
20,21,25,44-46
. 
Recommendation 7(2): 
Support and Clarity 
Ethics application: Each 
Committee should provide 
direct assistance, clear 
instructions, and training 
courses to support the 
researcher.  
Instructions and applications 
should be written in a simple, 
universally understood 
language.  
Fees: Administrative fees 
should exclusively be charged 
in non-academic research; if 
charged, they should not 
constitute an obstacle. 
Administrative support, training 
opportunities, and transparent, 
simple instructions will help 
facilitate the paediatric 
research ethics application. For 
investigator initiated, non-
commercial studies fees should 
not constitute a barrier to 
research. Fees should be set 
solely on the basis of cost 
recovery principles and be 
reduced or waived when 
appropriate 
20,21,28,47
. 
I A 
 
 
 
 
 
 
 
 
  
100% 
Paediatric Principles 
Recommendation 8: 
Subsidiarity 
A study that will produce 
generalizable results across all 
age groups should 
preferentially be performed in 
adults. 
Adults should be primarily 
included in research studies, 
since they are capable of giving 
truly informed consent. 
Children are a vulnerable 
population and need 
protection. Generalizable 
research has to be conducted in 
adults capable to consent 
20,22,23,25,27,33,41,42,44
. 
I A 88% 
Recommendation 9: 
Paediatric Rule 
Children should receive special 
Children are a vulnerable 
population. The potential risks 
including privacy risks related 
to genetic information, physical 
I A 100% 
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protection when included in 
data and biobank studies.  
and emotional harms, and 
disrespect of values should be 
minimized during sample 
collection and the duration of 
the research study. Justification 
is required when inviting 
vulnerable individuals to serve 
as research subjects, the risk 
should be minimal and the 
means of protecting rights and 
welfare must be strictly applied 
20,22,23,25,27,33,42,43,45,48
. 
Consent in Paediatric Research 
Recommendation 10: 
Integration of Minors 
Voluntary and age-
appropriate informed 
consent/assent has to be 
obtained from legal guardians 
and/or minors as appropriate 
according to the international 
guidelines (ICH, WHO, others) 
before paediatric data and 
biospecimen can be collected 
and used for research.  Minors 
should be integrated into the 
process of consent and those 
capable of forming an opinion 
and assessing the information 
given, should be asked to give 
assent or consent, as 
appropriate. 
Children have the right to be 
included in research and 
benefit from research 
discoveries. All research 
mandates voluntary, informed 
consent given by a competent 
individual, who has received 
the necessary information and 
has adequately understood the 
information. The decision to 
participate has to be reached 
without coercion, undue 
influence or intimidation. 
Informed consent embodies the 
individual's freedom of choice 
and respects the individual's 
autonomy. Legal guardians may 
serve as proxies for minors, 
who do not have full capacity, 
in the consent process; children 
should be integrated in the 
consent process and their 
opinion and views have to be 
respected 
12,20,22,23,25-
27,31,33,43,46,49-53
. 
I A 100% 
Recommendation 11: 
Enabling Informed Consent 
All information given to the 
child and the legal guardian 
should be age appropriate, 
The process of consenting must 
not be simply a ritual recitation 
of the contents of a written 
document. The information 
must be conveyed in language 
that suits the individual's level 
I B 100% 
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written, and presented by a 
competent person in the 
country’s official language. 
Paediatric participants and 
legal guardians should be 
granted appropriate time to 
make and reconsider their 
decision. Withdrawal of 
consent should be possible at 
any time of the study. 
of understanding. Parents/legal 
guardians and children must be 
given time and opportunity for 
discussion to make the decision 
without any pressure to 
consent. Participants should be 
informed that consent/assent 
can be withdrawn at any time.  
Exercising the right to withdraw 
cannot entail consequences in 
medical care services 
20,22,23,25-
27,43,46,48,49,52,54
. 
Recommendation 12: Scope 
of Consent 
The scope of consent should 
preferably be broad. Broad 
consent should include future 
research opportunities, 
possibility to share samples 
and data with national and/or 
international research 
partners.  Broad consent 
should include the possibility 
to re-contact participants. 
Consent forms need to be 
internationally harmonized to 
ensure international research 
projects. Consent forms have 
to include the possibility for 
specimen shipment and data 
transfer. Consenting should 
include the opportunity to opt 
out of certain aspects of 
research. 
Broad consent reduces the 
burden for participants as it 
avoids the need for re-sampling 
of biospecimen and re-
collection of data in addition to 
the need for re-consenting. 
Broad consent avoids the need 
to re-contact and re-consent 
participants, which may 
represent a significant barrier 
to conducting research. It 
allows for novel research to be 
conducted that had not been 
conceptualized at the time of 
the initial study. Permission for 
data and specimen transfer 
should be included in the 
harmonized consent forms.  A 
governance specification and 
an opt-out option have to be 
included enabling participants 
to limit the use of their 
specimens and data to distinct 
research questions 
22,26,27,30,37,43,45,48,55-57
. 
I B 100% 
Recommendation 13: Re-
consenting  
Paediatric participants that 
have previously only given 
assent should be re-contacted 
for consent to an ongoing 
study when reaching legal age. 
At time of reaching legal age 
the formal legal status of the 
participant changes. This 
mandates obtaining re-consent 
since the initial consent was not 
obtained from the minor and 
therefore has limited temporal 
I A 88% 
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Researchers should make 
considerable effort to re-
contact participants for 
further use of data and 
samples. The ethics 
committee should evaluate 
the option of further use of 
data and sample, if 
participants are not reachable. 
scope. Allowing the competent 
child a right to withdraw 
materials given into the 
biobank by proxy consent is 
consistent with the idea of a 
child's "right to an open 
future”, which states that 
choices made for a child when 
being a minor should not 
preclude the right to make 
decisions when reaching legal 
age. The former minor has now 
full autonomy and is now able 
to oversee the dimension of the 
research and can give informed 
consent for ongoing research 
generated from databases and 
biobanks. In case the 
participant cannot be reached, 
the researcher should seek 
advice from the ethics 
committee for further use of 
data and samples 
18,21,22,26,27,48,58,59
. 
Recommendation 14: 
Incidental Findings 
Researchers should partner 
with expert health care 
providers and inform patients 
and legal guardians about 
clinically relevant results. 
Participant’s refusal to be 
informed about clinically 
relevant results represents an 
exclusion criterion. 
In adults the principle of 
autonomy and the individual 
right “to know or not to know” 
defines the extent to which 
researchers should inform 
participants including children 
and their legal guardians about 
clinically relevant results 
detected in research studies. In 
paediatric studies, the proxy 
consent does not cover this 
decision.  Here, researchers 
have a moral duty to inform 
minor participants and their 
legal guardians about clinically 
relevant results that mandate 
action including research result 
and incidental findings. Findings 
should be communicated by an 
expert clinician 
20,22,23,25,27-
I B 100% 
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29,33,42,43,60
. 
Paediatric Data and Biobanks: Operational Principles 
Recommendation 15: 
Organizational Framework   
The organizational 
frameworks for collaborative 
paediatric data- and biobanks 
must include a governance 
structure. Terms of 
transparency, fair access to 
data and samples including 
ownership, authorship of 
research publications, 
payment, and reciprocity of 
sample sharing should be 
defined. Principles of 
interoperability should be 
followed. Data- and /or 
material transfer agreements 
should be elaborated and 
signed between research 
partners. Researchers should 
develop a long-term plan for 
sustainability. Biobanks should 
be captured in a central 
electronic tracking system. 
An organizational framework 
prevents ethical and legal 
conflicts, enables long-term 
collaborations between 
participating researchers. The 
development and endorsement 
of standards enables higher 
research interoperability. 
Transparency of the framework 
and its policies is necessary for 
biobanks in all levels. 
Standardized design and 
harmonization of data fields 
enables interoperability 
between biobanks.  A 
governance structure and a 
long-term sustainability plan 
will ensure public trust and long 
benefits. A central registry for 
European biobanks will not only 
reduce the burden of repeated 
sample collection but also helps 
to use existing resources in the 
most efficient way 
3,21,26-
28,33,37,43,57,61
. 
I B 100% 
Recommendation 16: 
Sampling 
Non-invasive sampling 
approaches should be 
preferentially used in children. 
Standard operating 
procedures (SOPs) of 
paediatric sample collection, 
processing, pre-analytic 
handling, and shipment should 
be defined and observed to 
ensure high quality specimen 
handling. 
The Paediatric Rule mandates 
minimal invasive sampling, 
which may result in small 
quantities of biospecimen and 
may require designated, 
harmonized SOPs. Processing of 
paediatric biospecimen and 
capture of paediatric data 
samples should include 
necessary measures to ensure 
the accuracy, reliability, quality, 
and security 
20,25,27,28,41,46,57,61,62
. 
I B 100%) 
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Sharing of Data and Samples     
Recommendation 17: Data 
Harmonization 
Collaborative databanks 
should built on available 
instruments of data 
harmonization, standardized 
access to data, define 
measures of high data quality 
including data dictionaries, 
and regulate data transfer. 
Harmonization of data fosters 
the interoperability of systems 
and facilitates the exchange of 
scientific data. High quality 
standards enable the possibility 
of international collaborative 
research with health related 
benefits for future generations. 
Quality assurance measures 
should be implemented, 
including conditions to ensure 
appropriate security and 
confidentiality during 
establishment of the collection, 
storage, use and, where 
appropriate, transfer of data 
and materials 
3,26-28,30,33,57,61,63
. 
I A 100% 
Recommendation 18: Data 
Protection  
Researchers should 
implement a state-of-the-art 
data and sample protection 
system. Secure coding of data 
and samples should ensure 
confidentiality while enabling 
withdrawal of consent, re-
consenting, and notification of 
clinically relevant results. 
Secure data-sample linkage 
systems should be 
established. 
Researchers are custodians of 
personal data and biospecimen. 
They are responsible for 
establishing a system of secure 
safeguards for privacy, 
confidentiality, and legitimate 
access.  While using anonymous 
data and samples is the best 
way to protect personal 
information, it is not feasible in 
paediatric research as it limits 
the researchers’ ability to act 
on withdrawal of consent, the 
need for re-consenting and the 
detection, and notification of 
clinically relevant results. All 
data handling has to follow the 
standards of the EU General 
Data Protection Regulation 
20,26,27,30,33,37,46,57,61,63
. 
I A 100% 
Recommendation 19: 
Standardization of Transfer 
Specimen transfer should 
include standardized 
packaging and labelling, 
Standardization of shipment in 
accordance with international 
regulations and laws including 
all accompanying documents 
ensures a safe and confidential 
transfer of biological materials 
I B 100% 
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accompanying transfer 
documentation, customs 
regulations, and sample 
tracking. The consent form 
must include the agreement 
to share data and samples. 
across borders.  A documented 
agreement between the sender 
of the biological materials and 
the recipient should be signed. 
The patient's agreement of data 
and specimen transfer has to be 
obtained and shared 
26-28,35,37
. 
Commercialization and Third Party Access 
Recommendation 20: Fees 
and Incentives 
Biobanks should enable 
research to improve medical 
knowledge. Provision of data 
and samples should be free; 
shipment and processing costs 
should be covered by the 
requesting research team. 
Participants or their parents 
should not receive payment. 
Responsible sharing of 
biospecimen and data should 
be guided by the principle of 
the “Universal Declaration of 
Human Rights, 1948”, which 
grants every individual the right 
to „share in scientific 
advancement and its benefits“.  
In fact, the Council of Europe 
states that sharing of all 
knowledge and distribution of 
materials will be obligatory.  
Collaborative paediatric 
research aims to maximize 
discoveries by sharing of 
resources, data, and samples. 
Financial incentives should be 
avoided. The operators of data 
and biobanks must ensure that 
any stratified access or fee 
policies are fair, transparent, 
and do not inhibit research 
20,25,26,28,33,37,39,61,64,65
. 
I A 100% 
Recommendation 21: Third 
Parties 
Researchers have to obtain 
ethics approval before giving 
patient data or sample access 
to third parties. Continuous 
education of the public about 
biobanks is important to 
retain public trust in research. 
The autonomy principle 
mandates that a patient has to 
give consent to any sharing of 
data and biospecimen. A 
researcher therefore should not 
share any data or specimens 
with third parties unless the 
patient permits such 
submission and an ethics 
approval was obtained. The 
most important prerequisite for 
successful biobank related 
research is ensuring the public 
I A 100% 
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trust. This can be achieved 
through continuous education 
of people and protection of 
privacy 
18,20,25,26,30,33,39,43,45
. 
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Table 1 Recommendations for collaborative paediatric research including biobanking in Europe 
Text of recommendations  Justification Evidence  Strength  Agree 
Guiding Principles 
Recommendation 1: Advancing Care and Discovery  
Research in children should be supported including international, multi-
centre data collection and banking and transfer of biological specimens. 
Collaboration enables discovery in paediatric diseases and care 
advancement for children, in particular for those with rare diseases. 
Discovery and care advancement in paediatric diseases requires 
collaborative longitudinal research projects of international scale in order 
to include sufficient numbers of participants and generate robust scientific 
data. The international collaborative collection, storage, and sharing of 
human biological material and associated clinical information reduce the 
overall burden of sampling for patients and researchers enabling sustained, 
high-quality research
2,13,14,18,29,31
. 
I B 100% 
Recommendation 2: Enabling Support 
Paediatric researchers should be offered research training opportunities, 
access to mentorship and guidance, protected time, and financial support 
to conduct paediatric research. Institutional resources for research 
protocol development, translation services, ethics submission, and 
research conduct should be made available. 
The complexity of collaborative paediatric diseases research and the 
heterogeneity of rules, regulations, and processes within and across 
European countries mandate researchers to develop distinct skill sets and 
content knowledge. Focused, comprehensive training, institutional 
assistance, and guidance partnered with financial and other support will 
enable researchers to overcome the disproportionally challenging barriers 
towards successful multi-national paediatric diseases research requiring 
sample and data collection 
2,16,24,32-34
. 
I B 100% 
Recommendation 3: Supportive Legislative Framework 
A supportive legislative framework for international collaborating 
biobanks is lacking. A framework (WHO, ICH, EMA, FDA, other) should be 
implemented to overcome legal and ethical barriers in international 
research. An international binding shipment and custom agreement for 
biological samples should be established. 
The regulatory requirements for paediatric biobanking vary significantly 
between European countries. This dramatically complicates the 
implementing of international paediatric diseases biobanks. A unified 
European framework should be developed and implemented in order to 
facilitate the international sharing of precious paediatric biospecimen and 
enable life-saving discoveries 
3,20,29,33,35-38
. 
II B 100% 
Ethics 
Recommendation 4: Centralized Ethics  
All international collaborative paediatric research should be reviewed by 
central European Ethics Committees. All auxiliary studies require 
additional review and approval. The review has to capture all ethical 
principles including privacy rights. 
Designated and highly qualified, independent, and centralized Ethics 
Committees should serve as Competent Authority for paediatric research. 
Subsequent, auxiliary studies should be reviewed by the same committee. 
The resulting single ethics vote captures the highest ethical principles and 
privacy standards. Subsequently National Ethics Committee reviews are 
solely tasked with evaluating cultural appropriateness 
16,17,19,21-23,29,37,39
. 
I B 94% 
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Recommendation 5: Standardization and Transparency 
All collaborative paediatric research applications in the European 
Community should be filed in a standardized format and be submitted to 
a central electronic application portal. Following submission the review 
process should be transparent and electronically traceable. 
The current necessity of multiple ethics applications, the large variability in 
the submitting formats, and the lack of transparency of the reviewing 
process hinder collaborative paediatric research within the EU. A 
standardized submission and approval process through a central application 
portal as implemented in the EU portal for all clinical trials will overcome 
this barrier and facilitate research and care advancement 
17
. 
I B 100% 
Recommendation 6: Central Competency 
The European Central Ethics Application Board should rapidly assess all 
multicentre applications for meeting formal EU-standards. All 
applications including timelines should be tracked in a central repository. 
The application should be transferred to the applicant's designated 
National Ethics Committee for Paediatric Research and Biobanking and 
undergo review including compliance with the specific ethical principles. 
After sign off, the other participating National Ethics Committees should 
rapidly adopt the decision. 
The standardization of application requirements and a unified primary, 
central review process overcomes barriers by simplifying the process while 
increasing the quality in accordance to the European regulation on clinical 
trials on medicinal products for human use (Clinical Trials Regulation)
17,40
. 
I B 100% 
Recommendation 7(1): Membership expertise 
Each National Ethics Committee for Paediatric Research and Biobanking 
should operate according to uniform standards. Membership: Each 
Committee has to include independent experts in paediatric research, lay 
members (non-professionals including patient / parent organizations or 
community advocates) and those with specific content expertise 
including genetics to review specific applications when appropriate. 
The ethics committee review of collaborative paediatric research studies 
and biobanking requires specific expertise reflected in its membership: 
Paediatricians should provide advice on clinical, ethical, and psychosocial 
aspects of research in minors. Lay members should offer support evaluating 
individual and societal impact of the proposed research. The review of 
genetic studies mandates an additional content expert for guidance
16,17,21,40-
42
. 
I A 94% 
Recommendation 7(2): Support and Clarity 
Ethics application: Each Committee should provide direct assistance, 
clear instructions, and training courses to support the researcher. 
Instructions and applications should be written in a simple, universally 
understood language. Fees: Administrative fees should exclusively be 
charged in non-academic research; if charged, they should not constitute 
an obstacle. 
Administrative support, training opportunities, and transparent, simple 
instructions will help facilitate the paediatric research ethics application. 
For investigator initiated, non-commercial studies fees should not 
constitute a barrier to research. Fees should be set solely on the basis of 
cost recovery principles and be reduced or waived when appropriate 
16,17,24,43
. 
I A 100% 
Paediatric Principles 
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Recommendation 8: Subsidiarity 
A study that will produce generalizable results across all age groups 
should preferentially be performed in adults. 
Adults should be primarily included in research studies, since they are 
capable of giving truly informed consent. Children are a vulnerable 
population and need protection. Generalizable research has to be 
conducted in adults capable to consent 
16,18,19,21,23,29,37,38,40
. 
I A 88% 
Recommendation 9: Paediatric Rule 
Children should receive special protection when included in data and 
biobank studies.  
Children are a vulnerable population. The potential risks including privacy 
risks related to genetic information, physical and emotional harms, and 
disrespect of values should be minimized during sample collection and the 
duration of the research study. Justification is required when inviting 
vulnerable individuals to serve as research subjects, the risk should be 
minimal and the means of protecting rights and welfare must be strictly 
applied 
16,18,19,21,23,29,38,39,41,44
. 
I A 100% 
Consent in Paediatric Research 
Recommendation 10: Integration of Minors 
Voluntary and age-appropriate informed consent/assent has to be 
obtained from legal guardians and/or minors as appropriate according to 
the international guidelines (ICH, WHO, others) before paediatric data 
and biospecimen can be collected and used for research.  Minors should 
be integrated into the process of consent and those capable of forming 
an opinion and assessing the information given, should be asked to give 
assent or consent, as appropriate. 
Children have the right to be included in research and benefit from research 
discoveries. All research mandates voluntary, informed consent given by a 
competent individual, who has received the necessary information and has 
adequately understood the information. The decision to participate has to 
be reached without coercion, undue influence or intimidation. Informed 
consent embodies the individual's freedom of choice and respects the 
individual's autonomy. Legal guardians may serve as proxies for minors, 
who do not have full capacity, in the consent process; children should be 
integrated in the consent process and their opinion and views have to be 
respected 
8,16,18,19,21-23,27,29,39,42,45-49
. 
I A 100% 
Recommendation 11: Enabling Informed Consent 
All information given to the child and the legal guardian should be age 
appropriate, written, and presented by a competent person in the 
country’s official language. Paediatric participants and legal guardians 
should be granted appropriate time to make and reconsider their 
decision. Withdrawal of consent should be possible at any time of the 
study. 
The process of consenting must not be simply a ritual recitation of the 
contents of a written document. The information must be conveyed in 
language that suits the individual's level of understanding. Parents/legal 
guardians and children must be given time and opportunity for discussion 
to make the decision without any pressure to consent. Participants should 
be informed that consent/assent can be withdrawn at any time.  Exercising 
the right to withdraw cannot entail consequences in medical care services 
16,18,19,21-23,39,42,44,45,48,50
. 
I B 100% 
Recommendation 12: Scope of Consent 
The scope of consent should preferably be broad. Broad consent should 
include future research opportunities, possibility to share samples and 
data with national and/or international research partners.  Broad consent 
should include the possibility to re-contact participants. Consent forms 
need to be internationally harmonized to ensure international research 
Broad consent reduces the burden for participants as it avoids the need for 
re-sampling of biospecimen and re-collection of data in addition to the 
need for re-consenting. Broad consent avoids the need to re-contact and 
re-consent participants, which may represent a significant barrier to 
conducting research. It allows for novel research to be conducted that had 
not been conceptualized at the time of the initial study. Permission for data 
and specimen transfer should be included in the harmonized consent 
I B 100% 
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projects. Consent forms have to include the possibility for specimen 
shipment and data transfer. Consenting should include the opportunity 
to opt out of certain aspects of research. 
forms.  A governance specification and an opt-out option have to be 
included enabling participants to limit the use of their specimens and data 
to distinct research questions 
18,22,23,26,33,39,41,44,51-53
. 
Recommendation 13: Re-consenting  
Paediatric participants that have previously only given assent should be 
re-contacted for consent to an ongoing study when reaching legal age. 
Researchers should make considerable effort to re-contact participants 
for further use of data and samples. The ethics committee should 
evaluate the option of further use of data and sample, if participants are 
not reachable. 
At time of reaching legal age the formal legal status of the participant 
changes. This mandates obtaining re-consent since the initial consent was 
not obtained from the minor and therefore has limited temporal scope. 
Allowing the competent child a right to withdraw materials given into the 
biobank by proxy consent is consistent with the idea of a child's "right to an 
open future”, which states that choices made for a child when being a 
minor should not preclude the right to make decisions when reaching legal 
age. The former minor has now full autonomy and is now able to oversee 
the dimension of the research and can give informed consent for ongoing 
research generated from databases and biobanks. In case the participant 
cannot be reached, the researcher should seek advice from the ethics 
committee for further use of data and samples 
14,17,18,22,23,44,54,55
. 
I A 88% 
Recommendation 14: Incidental Findings 
Researchers should partner with expert health care providers and inform 
patients and legal guardians about clinically relevant results. Participant’s 
refusal to be informed about clinically relevant results represents an 
exclusion criterion. 
In adults the principle of autonomy and the individual right “to know or not 
to know” defines the extent to which researchers should inform 
participants including children and their legal guardians about clinically 
relevant results detected in research studies. In paediatric studies, the 
proxy consent does not cover this decision.  Here, researchers have a moral 
duty to inform minor participants and their legal guardians about clinically 
relevant results that mandate action including research result and 
incidental findings. Findings should be communicated by an expert clinician 
16,18,19,21,23-25,29,38,39,56
. 
I B 100% 
Paediatric Data and Biobanks: Operational Principles 
Recommendation 15: Organizational Framework   
The organizational frameworks for collaborative paediatric data- and 
biobanks must include a governance structure. Terms of transparency, 
fair access to data and samples including ownership, authorship of 
research publications, payment, and reciprocity of sample sharing should 
be defined. Principles of interoperability should be followed. Data- and 
/or material transfer agreements should be elaborated and signed 
between research partners. Researchers should develop a long-term plan 
for sustainability. Biobanks should be captured in a central electronic 
tracking system. 
An organizational framework prevents ethical and legal conflicts, enables 
long-term collaborations between participating researchers. The 
development and endorsement of standards enables higher research 
interoperability. Transparency of the framework and its policies is necessary 
for biobanks in all levels. Standardized design and harmonization of data 
fields enables interoperability between biobanks.  A governance structure 
and a long-term sustainability plan will ensure public trust and long 
benefits. A central registry for European biobanks will not only reduce the 
burden of repeated sample collection but also helps to use existing 
resources in the most efficient way 
3,17,22-24,29,33,39,53,57
. 
I B 100% 
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Recommendation 16: Sampling 
Non-invasive sampling approaches should be preferentially used in 
children. Standard operating procedures (SOPs) of paediatric sample 
collection, processing, pre-analytic handling, and shipment should be 
defined and observed to ensure high quality specimen handling. 
The Paediatric Rule mandates minimal invasive sampling, which may result 
in small quantities of biospecimen and may require designated, harmonized 
SOPs. Processing of paediatric biospecimen and capture of paediatric data 
samples should include necessary measures to ensure the accuracy, 
reliability, quality, and security 
16,21,23,24,37,42,53,57,58
. 
I B 100%) 
Sharing of Data and Samples     
Recommendation 17: Data Harmonization 
Collaborative databanks should built on available instruments of data 
harmonization, standardized access to data, define measures of high data 
quality including data dictionaries, and regulate data transfer. 
Harmonization of data fosters the interoperability of systems and facilitates 
the exchange of scientific data. High quality standards enable the possibility 
of international collaborative research with health related benefits for 
future generations. Quality assurance measures should be implemented, 
including conditions to ensure appropriate security and confidentiality 
during establishment of the collection, storage, use and, where 
appropriate, transfer of data and materials 
3,22-24,26,29,53,57,59
. 
I A 100% 
Recommendation 18: Data Protection  
Researchers should implement a state-of-the-art data and sample 
protection system. Secure coding of data and samples should ensure 
confidentiality while enabling withdrawal of consent, re-consenting, and 
notification of clinically relevant results. Secure data-sample linkage 
systems should be established. 
Researchers are custodians of personal data and biospecimen. They are 
responsible for establishing a system of secure safeguards for privacy, 
confidentiality, and legitimate access.  While using anonymous data and 
samples is the best way to protect personal information, it is not feasible in 
paediatric research as it limits the researchers’ ability to act on withdrawal 
of consent, the need for re-consenting and the detection, and notification 
of clinically relevant results. All data handling has to follow the standards of 
the EU General Data Protection Regulation 
16,22,23,26,29,33,42,53,57,59
. 
I A 100% 
Recommendation 19: Standardization of Transfer 
Specimen transfer should include standardized packaging and labelling, 
accompanying transfer documentation, customs regulations, and sample 
tracking. The consent form must include the agreement to share data 
and samples. 
Standardization of shipment in accordance with international regulations 
and laws including all accompanying documents ensures a safe and 
confidential transfer of biological materials across borders.  A documented 
agreement between the sender of the biological materials and the recipient 
should be signed. The patient's agreement of data and specimen transfer 
has to be obtained and shared 
22-24,31,33
. 
I B 100% 
Commercialization and Third Party Access 
Recommendation 20: Fees and Incentives 
Biobanks should enable research to improve medical knowledge. 
Provision of data and samples should be free; shipment and processing 
costs should be covered by the requesting research team. Participants or 
their parents should not receive payment. 
Responsible sharing of biospecimen and data should be guided by the 
principle of the “Universal Declaration of Human Rights, 1948”, which 
grants every individual the right to „share in scientific advancement and its 
benefits“.  In fact, the Council of Europe states that sharing of all knowledge 
and distribution of materials will be obligatory.  Collaborative paediatric 
research aims to maximize discoveries by sharing of resources, data, and 
samples. Financial incentives should be avoided. The operators of data and 
biobanks must ensure that any stratified access or fee policies are fair, 
I A 100% 
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transparent, and do not inhibit research 
16,21,22,24,29,33,35,57,60,61
. 
Recommendation 21: Third Parties 
Researchers have to obtain ethics approval before giving patient data or 
sample access to third parties. Continuous education of the public about 
biobanks is important to retain public trust in research. 
The autonomy principle mandates that a patient has to give consent to any 
sharing of data and biospecimen. A researcher therefore should not share 
any data or specimens with third parties unless the patient permits such 
submission and an ethics approval was obtained. The most important 
prerequisite for successful biobank related research is ensuring the public 
trust. This can be achieved through continuous education of people and 
protection of privacy 
14,16,21,22,26,29,35,39,41
. 
I A 100% 
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Option 2 (for space constrains purposes) 
Table 1 Recommendations for collaborative paediatric research including biobanking in Europe 
Text of recommendations  Justification Evidence  Strength  Agree 
Guiding Principles 
Recommendation 1: Advancing Care and Discovery  
2,13,14,18,29,31
 I B 100% 
Recommendation 2: Enabling Support 
2,16,24,32-34
 I B 100% 
Recommendation 3: Supportive Legislative 
Framework 
3,20,29,33,35-38
 II B 100% 
Ethics 
Recommendation 4: Centralized Ethics  
16,17,19,21-23,29,37,39
 I B 94% 
Recommendation 5: Standardization and 
Transparency 
17
 I B 100% 
Recommendation 6: Central Competency 
17,40
 I B 100% 
Recommendation 7(1): Membership expertise 
16,17,21,40-42
 I A 94% 
Recommendation 7(2): Support and Clarity 
16,17,24,43
 I A 100% 
Paediatric Principles 
Recommendation 8: Subsidiarity  
16,18,19,21,23,29,37,38,40
 I A 88% 
Recommendation 9: Paediatric Rule  
16,18,19,21,23,29,38,39,41,44
 I A 100% 
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Consent in Paediatric Research 
Recommendation 10: Integration of Minors  
8,16,18,19,21-23,27,29,39,42,45-49
 I A 100% 
Recommendation 11: Enabling Informed Consent 
16,18,19,21-23,39,42,44,45,48,50
 I B 100% 
Recommendation 12: Scope of Consent 
18,22,23,26,33,39,41,44,51-53
 I B 100% 
Recommendation 13: Re-consenting  
14,17,18,22,23,44,54,55
 I A 88% 
Recommendation 14: Incidental Findings 
16,18,19,21,23-25,29,38,39,56
 I B 100% 
Paediatric Data and Biobanks: Operational Principles 
Recommendation 15: Organizational Framework   
3,17,22-24,29,33,39,53,57
 I B 100% 
Recommendation 16: Sampling 
16,21,23,24,37,42,53,57,58
 I B 100%) 
Sharing of Data and Samples     
Recommendation 17: Data Harmonization 
3,22-24,26,29,53,57,59
 I A 100% 
Recommendation 18: Data Protection  
16,22,23,26,29,33,42,53,57,59
 I A 100% 
Recommendation 19: Standardization of Transfer  
22-24,31,33
 I B 100% 
Commercialization and Third Party Access 
Recommendation 20: Fees and Incentives 
16,21,22,24,29,33,35,57,60,61
 I A 100% 
Recommendation 21: Third Parties 
14,16,21,22,26,29,35,39,41
 I A 100% 
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Figure 1  
Modified hierarchy of evidence pyramid for inclusion of normative documents  
Legend: The pyramid depicting the hierarchy of evidence was modified with guidance of the Cochrane 
collaboration to enable the inclusion of all available scientific evidence and international normative 
documents in the systematic review.  
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Figure 2  
Literature selection flow chart  
Legend: The search included the following MESH-terms: data collection, ethics, biological specimen banks, 
confidentiality, informed consent by minors, specimen handling, quality improvement, and jurisprudence. In 
addition, the following subheadings were used: legislation, classification, methods, organization, 
administration, standards, and instrumentation. The search was limited to literature relevant to the 
paediatric age group (0 to 18 years of age) and to Europe.  
 
Search strategy  
((((((( "Data Collection/ethics"[Mesh] OR "Data Collection/legislation and jurisprudence"[Mesh] ))) OR (((((( 
"Ethics/classification"[Mesh] OR "Ethics/ethics"[Mesh] OR "Ethics/legislation and jurisprudence"[Mesh] OR 
"Ethics/methods"[Mesh] OR "Ethics/organization and administration"[Mesh] OR "Ethics/standards"[Mesh] ))) 
OR ethics)) AND (( "Biological Specimen Banks/classification"[Mesh] OR "Biological Specimen 
Banks/ethics"[Mesh] OR "Biological Specimen Banks/instrumentation"[Mesh] OR "Biological Specimen 
Banks/legislation and jurisprudence"[Mesh] OR "Biological Specimen Banks/methods"[Mesh] OR "Biological 
Specimen Banks/organization and administration"[Mesh] OR "Biological Specimen Banks/standards"[Mesh] 
)))) OR (((( "Confidentiality/ethics"[Mesh] OR "Confidentiality/legislation and jurisprudence"[Mesh] OR 
"Confidentiality/organization and administration"[Mesh] OR "Confidentiality/standards"[Mesh] ))) AND (( 
"Biological Specimen Banks/classification"[Mesh] OR "Biological Specimen Banks/ethics"[Mesh] OR 
"Biological Specimen Banks/instrumentation"[Mesh] OR "Biological Specimen Banks/legislation and 
jurisprudence"[Mesh] OR "Biological Specimen Banks/methods"[Mesh] OR "Biological Specimen 
Banks/organization and administration"[Mesh] OR "Biological Specimen Banks/standards"[Mesh] )))) OR (( 
"Informed Consent By Minors/ethics"[Mesh] OR "Informed Consent By Minors/legislation and 
jurisprudence"[Mesh] OR "Informed Consent By Minors/organization and administration"[Mesh] OR 
"Informed Consent By Minors/standards"[Mesh] ))) OR ((((((( "Specimen Handling/ethics"[Mesh] OR 
"Specimen Handling/legislation and jurisprudence"[Mesh] ))) OR (("Specimen Handling/standards"[Majr]) 
AND "Quality Improvement"[Mesh])) OR (("Specimen Handling"[Mesh]) AND "Ethics"[Mesh])) OR 
(("Jurisprudence"[Majr]) AND "Specimen Handling"[Majr])) OR (((("Specimen Handling"[Majr]) And 
("legislation and jurisprudence" [Subheading]))) OR (("Specimen Handling"[Majr]) AND "ethics" 
[Subheading]))))) OR (( "Data Collection/ethics"[Majr:NoExp] OR "Data Collection/legislation and 
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jurisprudence"[Majr:NoExp] ))  
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Table S1 
Study characteristics of the 85 included publications  
Author Year Title Journal Study design Evidence 
level 
Nationality 
of first 
author 
J. Allen, P. McCarthy, E. M. 
Dempsey and J. O. 
Hourihane 
2013 Irish public would prefer legislation to protect Guthrie card 
archive rather than destroy it 
BMJ cross sectional 
study 
IV  Ireland 
V. Anastasova, A. 
Mahalatchimy, E. Rial-
Sebbag, J. M. Anto Boque, T. 
Keil, J. Sunyer, J. Bousquet 
and A. Cambon-Thomsen 
2013 Communica ion of results and disclosure of incidental findings 
in longitudinal paediatric research 
Pediatric Allergy and 
Immunology 
non-systematic 
review 
III France 
Ashcroft R.E., Goodenough 
T., Willamson E., Kent J. 
2003 Children´s consent to research participation: social context and 
personal experience invalidate fixed cutoff rules 
The American Journal 
of Bioethics 
expert opinion V b UK 
J. Balaguer, A. Canete, E. 
Costa, S. Oltra, M. 
Hernandez and V. Castel 
2006 Tumour banks in pediatric oncology Clin Transl Oncol cross sectional IV  Spain 
K. Birmingham and A. Doyle 2009 Ethics and governance of a longitudinal birth cohort Paediatr Perinat 
Epidemiol 
non-systematic 
review 
III  UK 
D. Budimir, O. Polasek, A. 
Marusic, I. Kolcic, T. 
Zemunik, V. Boraska, A. 
Jeroncic, M. Boban, H. 
Campbell and I. Rudan 
2011 Ethical aspects of human biobanks: a systematic review Croat Med J systematic review  II a Croatia 
A. Cambon-Thomsen, E. 
Rial-Sebbag and B. M. 
Knoppers 
2007 Trends in ethical and legal frameworks for the use of human 
biobanks 
Eur Respir J non-systematic 
review 
III France 
P. Chatzipantazi, K. M. Roy, 
S. O. Cameron, D. Goldberg, 
R. Welbury and J. Bagg 
2004 The feasibility and acceptability of collecting oral fluid from 
healthy children for anti-HCV testing 
Arch Dis Child cross sectional  IV  UK 
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D. Deplanque, G. Birraux, P.-
H. Bertoye, E. Postaire, N. 
Round Table and X. Giens 
2009 Collections of Human Biological Samples for Scientific 
Purposes. Why do Current Regulation Need to be Clarified and 
How? 
Therapie expert opinion V b France 
C. M. Douglas, C. G. van El, 
A. Faulkner and M. C. Cornel 
2012 Governing biological material at the intersection of care and 
research: the use of dried blood spots for biobanking 
Croat Med J expert opinion V b Netherlands 
I. Ellis, G. Mannion and A. 
Warren-Jones 
2003 Retained human tissues: a molecular genetics goldmine or 
modern grave robbing? A legal approach to obtaining and 
using stored human samples 
Med Law expert opinion V b UK 
S. Eriksson, A. T. Höglund 
and G. Helgesson 
2008 Do Ethical Guidelines Give Guidance?A Critical Examination of 
Eight Ethics Regulations 
Cambridge Quarterly 
of Healthcare Ethics 
cross sectional 
study 
IV   
I. Garcia-Merino, N. de las 
Cuevas, J. Luis Jimenez, A. 
Garcia, J. Gallego, C. Gomez, 
D. Garcia, M. Angeles 
Munoz-Fernandez and H. I. 
V. B. Spanish 
2010 Pediatric HIV BioBank: A New Role of the Spanish HIV BioBank 
in Pediatric HIV Research 
AIDS Res Hum 
Retroviruses 
cross-sectional 
study 
IV Spain 
N. A. A. Giesbertz, A. L. 
Bredenoord and J. J. M. van 
Delden 
2014 Clarifying assent in pediatric research European journal of 
human genetics : EJHG 
narrative literature 
review 
V a  Netherlands 
E. Gluckman 2000 Ethical and legal aspects of placental/cord blood banking and 
transplant 
Haematologica expert opinion V b  France 
B. Godard, J. Schmidtke, J.-J. 
Cassiman and S. Ayme 
2003 Data storage and DNA banking for biomedical research: 
informed consent, confidentiality, quality issues, ownership, 
return of benefits. A professional perspective 
European Journal of 
Human Genetics 
non-systematic 
review 
III France 
T. Goodenough, E. 
Williamson, J. Kent and R. 
Ashcroft 
2004 Ethical protection in research: including children in the debate Researchers and their 
"subjects" 
cross-sectional 
study 
IV UK 
T. Goodenough, E. 
Williamson, J. Kent and R. 
Ashcroft 
2011 ‘What Did You Think About That?’ Researching Children’s 
Perceptions of Participation in a Longitudinal Genetic 
Epidemiological Study 
Children and Society non-systematic 
literature review 
 III UK 
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M. G. Hansson 2009 Ethics and biobanks British Journal of 
Cancer 
non-systematic 
review 
III Sweden 
M. G. Hansson 2005 Building on relationships of trust in biobank research J Med Ethics Expert Opinion V b Sweden 
M. G. Hansson 2007 For the safety and benefit of current and future patients Pathobiology Expert Opinion V b Sweden 
S. O. Hansson 2004 The ethics of biobanks Cambridge Quarterly 
of Healthcare Ethics 
Expert opinion V b Sweden 
G. Helgesson and U. 
Swartling 
2008 Views on data use, confidentiality and consent in a predictive 
screening involving children 
J Med Ethics cross sectional IV Sweden 
G. Helgesson 2005 Children, longitudinal studies, and informed consent Medicine, Health Care 
and Philosophy  
narrative literature 
review 
V a Sweden 
G. Helgesson, M. G. 
Hansson, J. Ludvigsson and 
U. Swartling 
2010 What parents find important when participating in 
longitudinal studies: results from a questionnaire 
Clinical Ethics cross sectional 
study 
IV   
K. Hens, H. Nys, J. J. 
Cassiman and K. Dierickx 
2009 Biological sample collections from minors for genetic research: 
a systematic review of guidelines and position papers 
Eur J Hum Genet systematic review II a Belgium 
K. Hens, H. Nys, J.-J. 
Cassiman and K. Dierickx 
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Last version 2013 
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International declaration on human genetic data 
I   International guideline regarding biomedical 
research and biobanks 
World Health Organization (WHO) 2003 
Genetic databases. Assessing the benefits and the impact on human and patient rights 
I International guideline regarding biomedical 
research and biobanks 
Organization of Economic Co-operation and Development (OECD) 2009 
Recommendation on Human Bioanks and Genetic Research Databases 
I International guideline regarding biomedical 
research and biobanks 
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I European legislation  
Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 
on the protection of natural persons with regard to the processing of personal data and 
on the free movement of such data, and repealing Directive 95/46/EC (General Data 
Protection Regulation) 
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Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States 
on research on biological materials of human origin 
(Adopted by the Committee of Ministers on 11 May 2016 
at the 1256th meeting of the Ministers’ Deputies) 
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Data storage and DNA banking for biomedical research: technical, social and ethical issues 
Recommendations of the European Society of Human Genetics 
European Journal of Human Genetics (2003) 11, Suppl 2, S8 –S10. 
doi:10.1038/sj.ejhg.5201115 
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Supplement Table S1 
Study characteristics of the 85 included publications  
Author Year Title Journal Study design Evidence 
level 
Nationality 
of first 
author 
J. Allen, P. McCarthy, E. M. 
Dempsey and J. O. 
Hourihane 
2013 Irish public would prefer legislation to protect Guthrie card 
archive rather than destroy it 
BMJ cross sectional 
study 
IV  Ireland 
V. Anastasova, A. 
Mahalatchimy, E. Rial-
Sebbag, J. M. Anto Boque, T. 
Keil, J. Sunyer, J. Bousquet 
and A. Cambon-Thomsen 
2013 Communica ion of results and disclosure of incidental findings 
in longitudinal paediatric research 
Pediatric Allergy and 
Immunology 
non-systematic 
review 
III France 
Ashcroft R.E., Goodenough 
T., Willamson E., Kent J. 
2003 Children´s consent to research participation: social context and 
personal experience invalidate fixed cutoff rules 
The American Journal 
of Bioethics 
expert opinion V b UK 
J. Balaguer, A. Canete, E. 
Costa, S. Oltra, M. 
Hernandez and V. Castel 
2006 Tumour banks in pediatric oncology Clin Transl Oncol cross sectional IV  Spain 
K. Birmingham and A. Doyle 2009 Ethics and governance of a longitudinal birth cohort Paediatr Perinat 
Epidemiol 
non-systematic 
review 
III  UK 
D. Budimir, O. Polasek, A. 
Marusic, I. Kolcic, T. 
Zemunik, V. Boraska, A. 
Jeroncic, M. Boban, H. 
Campbell and I. Rudan 
2011 Ethical aspects of human biobanks: a systematic review Croat Med J systematic review  II a Croatia 
A. Cambon-Thomsen, E. 
Rial-Sebbag and B. M. 
Knoppers 
2007 Trends in ethical and legal frameworks for the use of human 
biobanks 
Eur Respir J non-systematic 
review 
III France 
P. Chatzipantazi, K. M. Roy, 
S. O. Cameron, D. Goldberg, 
R. Welbury and J. Bagg 
2004 The feasibility and acceptability of collecting oral fluid from 
healthy children for anti-HCV testing 
Arch Dis Child cross sectional  IV  UK 
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D. Deplanque, G. Birraux, P.-
H. Bertoye, E. Postaire, N. 
Round Table and X. Giens 
2009 Collections of Human Biological Samples for Scientific 
Purposes. Why do Current Regulation Need to be Clarified and 
How? 
Therapie expert opinion V b France 
C. M. Douglas, C. G. van El, 
A. Faulkner and M. C. Cornel 
2012 Governing biological material at the intersection of care and 
research: the use of dried blood spots for biobanking 
Croat Med J expert opinion V b Netherlands 
I. Ellis, G. Mannion and A. 
Warren-Jones 
2003 Retained human tissues: a molecular genetics goldmine or 
modern grave robbing? A legal approach to obtaining and 
using stored human samples 
Med Law expert opinion V b UK 
S. Eriksson, A. T. Höglund 
and G. Helgesson 
2008 Do Ethical Guidelines Give Guidance?A Critical Examination of 
Eight Ethics Regulations 
Cambridge Quarterly 
of Healthcare Ethics 
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study 
IV   
I. Garcia-Merino, N. de las 
Cuevas, J. Luis Jimenez, A. 
Garcia, J. Gallego, C. Gomez, 
D. Garcia, M. Angeles 
Munoz-Fernandez and H. I. 
V. B. Spanish 
2010 Pediatric HIV BioBank: A New Role of the Spanish HIV BioBank 
in Pediatric HIV Research 
AIDS Res Hum 
Retroviruses 
cross-sectional 
study 
IV Spain 
N. A. A. Giesbertz, A. L. 
Bredenoord and J. J. M. van 
Delden 
2014 Clarifying assent in pediatric research European journal of 
human genetics : EJHG 
narrative literature 
review 
V a  Netherlands 
E. Gluckman 2000 Ethical and legal aspects of placental/cord blood banking and 
transplant 
Haematologica expert opinion V b  France 
B. Godard, J. Schmidtke, J.-J. 
Cassiman and S. Ayme 
2003 Data storage and DNA banking for biomedical research: 
informed consent, confidentiality, quality issues, ownership, 
return of benefits. A professional perspective 
European Journal of 
Human Genetics 
non-systematic 
review 
III France 
T. Goodenough, E. 
Williamson, J. Kent and R. 
Ashcroft 
2004 Ethical protection in research: including children in the debate Researchers and their 
"subjects" 
cross-sectional 
study 
IV UK 
T. Goodenough, E. 
Williamson, J. Kent and R. 
Ashcroft 
2011 ‘What Did You Think About That?’ Researching Children’s 
Perceptions of Participation in a Longitudinal Genetic 
Epidemiological Study 
Children and Society non-systematic 
literature review 
 III UK 
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M. G. Hansson 2009 Ethics and biobanks British Journal of 
Cancer 
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review 
III Sweden 
M. G. Hansson 2005 Building on relationships of trust in biobank research J Med Ethics Expert Opinion V b Sweden 
M. G. Hansson 2007 For the safety and benefit of current and future patients Pathobiology Expert Opinion V b Sweden 
S. O. Hansson 2004 The ethics of biobanks Cambridge Quarterly 
of Healthcare Ethics 
Expert opinion V b Sweden 
G. Helgesson and U. 
Swartling 
2008 Views on data use, confidentiality and consent in a predictive 
screening involving children 
J Med Ethics cross sectional IV Sweden 
G. Helgesson 2005 Children, longitudinal studies, and informed consent Medicine, Health Care 
and Philosophy  
narrative literature 
review 
V a Sweden 
G. Helgesson, M. G. 
Hansson, J. Ludvigsson and 
U. Swartling 
2010 What parents find important when participating in 
longitudinal studies: results from a questionnaire 
Clinical Ethics cross sectional 
study 
IV   
K. Hens, H. Nys, J. J. 
Cassiman and K. Dierickx 
2009 Biological sample collections from minors for genetic research: 
a systematic review of guidelines and position papers 
Eur J Hum Genet systematic review II a Belgium 
K. Hens, H. Nys, J.-J. 
Cassiman and K. Dierickx 
2009 Genetic Research on Stored Tissue Samples From Minors: A 
Systematic Review of the Ethical Literature 
Am J Med Genet A systematic review II a Belgium 
K. Hens, J. J. Cassiman, H. 
Nys and K. Dierickx 
2011 Children, biobanks and the scope of parental consent Eur J Hum Genet non-systematic 
review 
III Belgium 
K. Hens, E. Levesque and K. 
Dierickx 
2011 Children and biobanks: a review of the ethical and legal 
discussion 
Hum Genet non-systematic 
review 
III Belgium 
Page 96 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
K. Hens, C. E. Van El, P. 
Borry, A. Cambon-Thomsen, 
M. C. Cornel, F. Forzano, A. 
Lucassen, C. Patch, L. 
Tranebjaerg, E. Vermeulen, 
E. Salvaterra, A. Tibben and 
K. Dierickx 
2013 Developing a policy for paediatric biobanks: principles for good 
practice 
Eur J Hum Genet non-systematic 
review 
III Belgium 
K. Hens and K. Dierickx 2010 Human tissue samples for research. A focus group study in 
adults and teenagers in Flanders 
Genet Couns cross-sectional 
study 
IV Belgium 
K. Hens, H. Nys, J. J. 
Cassiman and K. Dierickx 
2011 The storage and use of biological tissue samples from minors 
for research: a focus group study 
Public Health 
Genomics 
cross-sectional 
study 
IV Belgium 
K. Hens, J. Snoeck, H. Nys, J. 
J. Cassiman and K. Dierickx 
2010 An exploratory survey of professionals on the use of stored 
tissue samples from minors for genetic research 
 Genetics and 
Molecular Research  
cross-sectional 
study 
IV Belgium 
K. Hens, H. Nys, J. J. 
Cassiman and K. Dierickx 
2011 Risks, Benefits, Solidarity: A Framework for the Participation of 
Children in Genetic Biobank Research 
Journal of Pediatrics narrative literature 
review 
V a Belgium 
K. Hens, H. Nys, J. J. 
Cassiman and K. Dierickx 
2011 The return of individual research findings in paediatric genetic 
research 
J Med Ethics narrative literature 
review 
V a Belgium 
K. Hens, J. Wright and K. 
Dierickx 
2009 Biobanks: oversight offers protection Science Letter to the editor V b Belgium 
B. Hofmann 2009 Broadening consent-and diluting ethics? J Med Ethics narrative literature 
review 
V a Norway 
S. Holm 2005 Informed Consent and the Bio-banking of Material from 
Children 
Genomics, society and 
politics 
expert opinion V b UK 
C. Jackson, M. Dixon-
Woods, M. Tobin, B. Young, 
D. Heney and K. Pritchard-
Jones 
2009 Seeking consent to tissue banking: a survey of health 
professionals in childhood cancer 
Eur J Cancer Care 
(Engl) 
cross sectional IV UK 
Page 97 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
V. W. V. Jaddoe, R. Bakker, 
C. M. van Duijn, A. J. van der 
Heijden, J. Lindemans, J. P. 
Mackenbach, H. A. Moll, E. 
A. P. Steegers, H. Tiemeier, 
A. G. Uitterlinden, F. C. 
Verhulst and A. Hofman 
2007 The Generation R Study Biobank: a resource for 
epidemiological studies in children and their parents 
European Journal of 
Epidemiology 
Observational 
Study 
III Netherlands 
S. Kirk 2007 Methodological and ethical issues in conducting qualitative 
research with children and young people: a literature review 
Int J Nurs Stud non-systematic 
review 
III UK 
M. F. Laker 2006 The Human Tissue Act: implications for clinical biochemistry Ann Clin Biochem expert opinion V b UK 
V. Lambert and M. Glacken 2011 Engaging with children in research: Theoretical and practical 
implications of negotiating informed consent/assent 
Nurs Ethics non-systematic 
review 
III Ireland 
H. Lochmuller and P. 
Schneiderat 
2010 Biobanking in Rare Disorders Rare Diseases 
Epidemiology 
expert opinion V b UK 
N. Martin, P. Krol, S. Smith, 
K. Murray, C. A. Pilkington, 
J. E. Davidson, L. R. 
Wedderburn and G. Juvenile 
Dermatomyositis Res 
2011 A national registry for juvenile dermatomyositis and other 
paediatric idiopathic inflammatory myopathies: 10 years' 
experience; the Juvenile Dermatomyositis National (UK and 
Ireland) Cohort Biomarker Study and Repository for Idiopathic 
Inflammatory Myopathies 
Rheumatology cross-sectional 
study 
IV UK 
D. Mascalzoni, A. C. J. W. 
Janssens, A. Stewart, P. 
Pramstaller, U. Gyllensten, I. 
Rudan, C. M. van Duijn, J. F. 
Wilson, H. Campbell, R. Mc 
Quillan and E. Consortium 
2010 Comparison of participant information and informed consent 
forms of five European studies in genetic isolated populations 
European Journal of 
Human Genetics 
expert opinion V b Italy 
J. V. McHale 2011 Accountability, Governance and Biobanks: The Ethics and 
Governance Committee as Guardian or as Toothless Tiger? 
Health Care Anal narrative literature 
review 
V a UK 
J. McHale, M. Habiba, M. 
Dixon-Woods, D. Cavers, D. 
Heney and K. Pritchard-
Jones 
2007 Consent for childhood cancer tissue banking in the UK: the 
effect of the Human Tissue Act 2004 
Lancet Oncol narrative literature 
review 
V a UK 
Page 98 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
D. F. Merlo, L. E. Knudsen, K. 
Matusiewicz, L. Niebroj and 
K. H. Vahakangas 
2007 Ethics in studies on children and environmental health J Med Ethics narrative literature 
review 
V a Italy 
D. F. Merlo, K. Vahakangas 
and L. E. Knudsen 
2008 Scientific integrity: critical issues in environmental health 
research. 
Environmental Health narrative literature 
review 
V a Italy 
S. E. Mumford 1999 Children of the 90s II: challenges for the ethics and law 
committee 
Arch Dis Child Fetal 
Neonatal Ed 
expert opinion V b UK 
S. E. Mumford 1999 Children of the 90s: ethical guidance for a longitudinal study Arch Dis Child Fetal 
Neonatal Ed 
expert opinion V b UK 
B. Norgaard-Pedersen and 
D. M. Hougaard 
2007 Storage policies and use of the Danish Newborn Screening 
Biobank 
J Inherit Metab Dis expert opinion V a Denmark 
B. Norgaard-Pedersen and 
H. Simonsen 
1999 Biological specimen banks in neonatal screening Acta Paediatr Suppl expert opinion V a Denmark 
J. Pawlikowski, J. Sak and K. 
Marczewski 
2011 Biobank research and ethics: the problem of informed consent 
in Polish biobanks 
Archives of Medical 
Science 
cross-sectional 
study 
IV Poland 
C. Petrini and M. Farisco 2011 Informed consent for cord blood donation. A theoretical and 
empirical study 
Blood Transfus cross-sectional 
study 
IV Italy 
C. Petrini, L. Lombardini, S. 
Pupella, A. N. Costa and G. 
Grazzini 
2011 Collection, Storage, and Allogeneic Use of Cord Blood: 
Informed Consent Form Used by the Italian Biobank Network 
Biopreservation and 
biobanking 
expert opinion IV Italy 
C. Petrini, A. Olivieri, C. 
Corbetta, R. Cerone, G. 
D'Agnolo and A. Bompiani 
2012 Common criteria among States for storage and use of dried 
blood spot specimens after newborn screening 
Ann Ist Super Sanita expert opinion V a Italy 
C. Petrini 2012 Ethical and legal considerations regarding the ownership and 
commercial use of human biological materials and their 
derivatives 
Journal of Blood 
Medicine 
narrative literature 
review 
V a Italy 
Page 99 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
W. Pinxten and K. Dierickx 2008 The Implementation of Directive 2001/20/EC into Belgian Law 
and the Specific Provisions on Pediatric Research 
European Journal of 
Health Law 15 (2008) 
153-161 
expert opinion V b Belgium 
W. Pinxten, K. Dierickx and 
H. Nys 
2009 Ethical principles and legal requirement for pediatric research 
in the EU: an analysis of the European normative and legal 
framework surrounding pediatric clinical trials 
Eur J  Pediatr expert opinion V b Belgium 
O. Polasek 2013 Future of biobanks - bigger, longer, and more dimensional Croat Med J narrative literature 
review 
V a Croatia 
M. M. Reid 1994 Research on leukaemia cells surplus to diagnostic needs in 
children 
J Med Ethics expert opinion V b UK 
K. Rushforth and P. A. 
McKinney 
2005 Issues of patient consent: a study of paediatric high-
dependency care 
Br J Nurs narrative literature 
review 
V a UK 
E. Salvaterra, F. Locatelli, S. 
Strazzer, R. Borgatti, G. 
D'Angelo and L. Lenzi 
2014 Paediatric Biobanks: Opinions, Feelings and Attitudes of 
Parents towards the Specimen Donation of Their Sick Children 
to a Hypothetical Biobank 
Pathobiology cross-sectional 
study 
IV Italy 
E. Salvaterra, R. Giorda, M. 
T. Bassi, R. Borgatti, L. E. 
Knudsen, A. Martinuzzi, M. 
Nobile, U. Pozzoli, G. P. 
Ramelli, G. L. Reni, D. 
Rivolta, M. A. Stazi, S. 
Strazzer, C. Thijs, V. 
Toccaceli, A. Trabacca, A. C. 
Turconi, S. Zanini, C. Zucca, 
N. Bresolin and L. Lenzi  
2012 Pediatric Biobanking: A Pilot Qualitative Survey of Practices, 
Rules, and Researcher Opinions in Ten European Countries 
Biopreservation and 
Biobanking 
cross-sectional 
study 
IV Italy 
N. J. Sebire and M. Dixon-
Woods 
2007 Towards a new era of tissue-based diagnosis and research Chronic Illness narrative literature 
review 
V a UK 
C. Soto, C. Tarrant, K. 
Pritchard-Jones and M. 
Dixon-Woods 
2012 Consent to tissue banking for research: qualitative study and 
recommendations 
Arch Dis Child cross-sectional 
study 
IV UK 
Page 100 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
S. Sterckx and K. Van Assche 2011 The New Belgian Law on Biobanks: Some Comments from an 
Ethical Perspective 
Health Care Anal expert opinon V b Belgium 
U. G. Stolt, P. E. Liss, T. 
Svensson and J. Ludvigsson 
2002 Attitudes to bioethical issues: a case study of a screening 
project 
Social Science and 
Medicine 
cross-sectional 
study 
IV Sweden 
U. G. Stolt, G. Helgesson, P. 
E. Liss, T. Svensson and 
J. Ludvigsson 
2005 Information and informed consent in a longitudinal 
screening involving children: a questionnaire survey 
European Journal of 
Human Genetics  
cross sectional 
study 
IV   
L. Stultiëns, T. Goffin, P. 
Borry, K. Dierickx and H. Nys 
2007 Mi ors and informed consent: a comparative approach. Eur J Health Law non-systematic 
review 
III Belgium 
U. Swartling, G. Helgesson, 
M. G. Hansson and J. 
Ludvigsson 
2008 Parental authority, research interests and children’s 
right to decide in medical research – an uneasy 
tension? 
Clinical Ethics cross sectional 
study 
IV   
U. Swartling, G. Helgesson, 
M. G. Hansson and J. 
Ludvigsson 
2009 Split views among parents regarding children’s right 
to decide about participation in research: a 
questionnaire survey 
Research ethics cross sectional 
study 
IV   
L. Taylor, D. Casson and M. 
J. Platt 
2003 Issues and experience around the Paediat ic Register of 
Inflammatory Bowel Disease 
Arch Dis Child expert opinion V b UK 
V. Toccaceli, L. Serino and 
M. A. Stazi 
2014 Informed consent, and an ethico- legal framework for 
paediatric observational research and biobanking: the 
experience of an Italian birth cohort study 
Cell and Tissue 
Banking 
non-systematic 
review 
III Italy 
P. Tozzo, R. Pegoraro and L. 
Caenazzo 
2010 Biobanks for non-clinical purposes and the new law on forensic 
biobanks: does the Italian context protect the rights of minors? 
J Med Ethics Expert opinion Vb Italy 
A. Martin Uranga, M. C. 
Martin Arribas, C. Jaeger 
and M. Posadas 
2005 Outstanding ethical-legal issues on biobanks. An overview on 
the regulations of the Member States of the Eurobiobank 
project 
Book chapter expert opinion V b Spain 
K. Vahakangas 2013 Research ethics in the post-genomic era Environmental and 
MolecularMutagenesis 
non-systematic 
review 
III Finland 
Page 101 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
S. van der Pal, B. Sozanska, 
D. Madden, A. Kosmeda, A. 
Debinska, H. Danielewicz, A. 
Boznanski and S. Detmar  
2011 Opinions of Children about Participation in Medical Genetic 
Research 
Puplic Health 
Genomics 
cross-sectional 
study 
IV Netherlands 
M. Waligora, V. Dranseika 
and J. Piasecki 
2014 Child's assent in research: age threshold or personalisation? BMC Med Ethics expert opinion V b Poland 
A. E. Westra, J. M. Wit, R. N. 
Sukhai and I. D. de Beaufort 
2011 Regulating "higher risk, no direct benefit" studies in minors The American Journal 
of Bioethics 
expert opinion V b Netherlands 
R. Wheeler 2012 Competent for confidence at 12 years of age? Arch Dis Child expert opinion V b UK 
G. Williams  2012 Children as means and ends in large-scale medical research bioethics Expert opinion Vb Eb 
E. Williamson 2005 Conducting research with children: The limits of confidentiality 
and child protection protocols 
Children and Society expert opinion V b UK 
 
  
Page 102 of 103
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Table Appendix 3:S2  
Characteristics of the included 16 normative documents 
 
Title Evidence Type of normative document 
United Nations (UN) Universal Declaration of Human Rights, 1948 I International declaration  
United Nations (UN) Convention on the rights of the child 1989 
(based on Declaration of the Rights of the Child) 
I International declaration  
World Medical Association (WMA) Declaration of Helsinki  
Last version 2013 
I International declaration  
United Nations Educational, Scientific and Cultural Organization (UNESCO) 2003  
International Bioethics Committee (IBC) 
International declaration on human genetic data 
I   International guideline regarding biomedical 
research and biobanks 
World Health Organization (WHO) 2003 
Genetic databases. Assessing the benefits and the impact on human and patient rights 
I International guideline regarding biomedical 
research and biobanks 
Organization of Economic Co-operation and Development (OECD) 2009 
Recommendation on Human Bioanks and Genetic Research Databases 
I International guideline regarding biomedical 
research and biobanks 
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